Abdominal Aortic Aneurysm

Complex MONDO:0005350 Pathograph 19 Show in embeddings browser

Abdominal aortic aneurysm (AAA) is a localized dilatation of the infrarenal aorta and a common degenerative vascular disease of older adults. It is multifactorial, with smoking, male sex, older age, and a positive family history as the principal risk factors. The aneurysmal wall is characterized by chronic transmural inflammation, matrix metalloproteinase (MMP)-driven proteolysis of elastin and fibrillar collagen, medial vascular smooth muscle cell depletion, and progressive thinning and weakening of the media and adventitia. Aneurysms are typically asymptomatic and enlarge silently; when wall stress exceeds wall strength the aneurysm ruptures, causing life-threatening haemorrhage with very high mortality. Management centers on ultrasound surveillance of small aneurysms, cardiovascular risk-factor modification, and elective open or endovascular repair once the aneurysm reaches a threshold diameter or rupture risk. This entry models common degenerative AAA; infected, inflammatory/IgG4-related, syndromic, and other uncommon aneurysm etiologies have distinct mechanisms and are not treated as subtypes of common AAA here.

Ask OpenScientist

Ask a research question about Abdominal Aortic Aneurysm. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
8
Pathophys.
7
Phenotypes
19
Pathograph
1
Genes
7
Medical Actions
4
Datasets
1
Deep Research
👪

Inheritance

1
Multifactorial polygenic inheritance HP:0010982
Common degenerative AAA has substantial heritability but no single Mendelian inheritance pattern. Risk reflects many common variants together with major environmental and demographic factors, particularly smoking, age, and sex.
Polygenic inheritance
Show evidence (1 reference)
PMID:37845353 SUPPORT Human Clinical
"Abdominal aortic aneurysm (AAA) is a common disease with substantial heritability. In this study, we performed a genome-wide association meta-analysis from 14 discovery cohorts and uncovered 141 independent associations, including 97 previously unreported loci."
A large multi-cohort GWAS establishes substantial heritability and a highly polygenic risk architecture.
⚙

Pathophysiology

8
PCSK9 and atherogenic-lipoprotein susceptibility axis
Human genetic analyses implicate non-HDL cholesterol and genetically predicted circulating PCSK9 in susceptibility to developing AAA. This is a risk axis rather than proof that PCSK9 determines the growth or rupture of an established aneurysm.
PCSK9 hgnc:20001 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PCSK9 (hgnc:20001). hgnc:20001 is a gene from the HUGO Gene Nomenclature Committee.
cholesterol metabolic process GO:0008203 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cholesterol metabolic process (GO:0008203). GO:0008203 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Progressive aortic dilatation In an elastase mouse model, Pcsk9 loss of function blunted experimental AAA growth, linking this susceptibility axis to dilatation in that model; this does not establish an effect on established human AAA.
Show evidence (1 reference)
PMID:37845353 SUPPORT Computational
"this was supported by evidence of significant colocalization between PCSK9 protein quantitative trait loci (pQTL) and AAA GWAS at the PCSK9 locus"
Mendelian-randomization and colocalization analyses support a PCSK9-linked susceptibility mechanism for incident AAA, without establishing an effect on growth or rupture of an existing aneurysm.
Aortic wall inflammatory cell infiltration
Chronic transmural inflammation of the aortic wall, with infiltration of macrophages and lymphocytes, is an early and sustained feature of AAA. The inflammatory infiltrate drives local production of proteolytic enzymes and pro-inflammatory cytokines (e.g., IL-6) that promote extracellular matrix breakdown and aneurysm progression.
macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology. T cell CL:0000084 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves T cell (CL:0000084). CL:0000084 is a cell type from the Cell Ontology.
inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Matrix metalloproteinase-mediated aortic wall proteolysis Infiltrating macrophages secrete proteolytic enzymes that degrade the aortic extracellular matrix.
Show evidence (2 references)
PMID:37799778 SUPPORT Human Clinical
"Pathological observations advocate inflammatory cell infiltration alongside adverse extracellular matrix degradation as key contributing factors to the formation of human atherosclerotic AAAs."
Human pathology observations identify inflammatory cell infiltration as a key contributor to AAA formation.
PMID:29945457 SUPPORT Human Clinical
"blood concentrations of MMP-9 and IL-6 measured in middle age predicted the risk of AAA during 24 years of follow-up."
In the ARIC cohort, circulating IL-6 prospectively predicted future AAA. This supports an association with the inflammatory axis but does not by itself establish that IL-6 is an upstream causal driver in the aortic wall.
Matrix metalloproteinase-mediated aortic wall proteolysis
Macrophage- and smooth muscle cell-derived matrix metalloproteinases (notably MMP-2 and MMP-9) are the predominant proteinases in the AAA wall. A shift in the balance between MMPs and their tissue inhibitors (TIMPs) toward net proteolysis drives destruction of the load-bearing matrix. MMP-9 is elevated in the circulation of patients who later develop AAA.
macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology. vascular smooth muscle cell CL:0000359 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vascular smooth muscle cell, annotated with vascular associated smooth muscle cell (CL:0000359). CL:0000359 is a cell type from the Cell Ontology.
extracellular matrix disassembly GO:0022617 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased extracellular matrix disassembly (GO:0022617). GO:0022617 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Elastin and collagen extracellular matrix degradation MMP activity degrades the elastin and fibrillar collagen that provide aortic wall strength.
Show evidence (2 references)
PMID:37799778 SUPPORT Human Clinical
"macrophage production of proteolytic enzymes is deemed responsible for the damaging loss of ECM proteins, especially elastin and fibrillar collagens, which characterise AAA progression and rupture."
Identifies macrophage-derived proteolytic enzymes as responsible for the matrix loss that characterizes AAA progression and rupture.
PMID:29945457 SUPPORT Human Clinical
"Higher concentrations of MMP-9 and IL-6 were associated with future risk of clinically diagnosed AAA"
Circulating MMP-9 prospectively associated with future AAA in a human cohort. This is consistent with, but does not directly demonstrate, MMP-9-mediated proteolysis within the aneurysmal wall.
Elastin and collagen extracellular matrix degradation
Proteolytic loss of medial elastic lamellae and fibrillar collagen removes the principal load-bearing components of the aortic wall. Elastin fragmentation reduces recoil and compliance, while collagen degradation ultimately compromises tensile strength and predisposes to rupture.
vascular smooth muscle cell CL:0000359 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vascular smooth muscle cell, annotated with vascular associated smooth muscle cell (CL:0000359). CL:0000359 is a cell type from the Cell Ontology.
collagen catabolic process GO:0030574 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased collagen catabolic process (GO:0030574). GO:0030574 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Progressive aortic dilatation Loss of load-bearing elastin and collagen weakens the wall and permits progressive dilatation.
Medial smooth muscle cell depletion and wall thinning Extracellular-matrix degradation is one proposed inducer of medial VSMC apoptosis in AAA.
Show evidence (1 reference)
PMID:30337540 SUPPORT Human Clinical
"AAA results from changes in the aortic wall structure, including thinning of the media and adventitia due to the loss of vascular smooth muscle cells and degradation of the extracellular matrix."
The definitive AAA review attributes AAA to extracellular matrix degradation and wall thinning.
Medial smooth muscle cell depletion and wall thinning
Apoptosis and loss of medial vascular smooth muscle cells, the cells that synthesize and maintain the aortic matrix, thins the media and adventitia and impairs the wall's capacity to repair ongoing matrix injury.
vascular smooth muscle cell CL:0000359 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vascular smooth muscle cell, annotated with vascular associated smooth muscle cell (CL:0000359). CL:0000359 is a cell type from the Cell Ontology.
apoptotic process GO:0006915 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased apoptotic process (GO:0006915). GO:0006915 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Progressive aortic dilatation A weakened, thinned wall permits progressive aneurysmal dilatation.
Show evidence (1 reference)
PMID:30337540 SUPPORT Human Clinical
"thinning of the media and adventitia due to the loss of vascular smooth muscle cells"
Loss of vascular smooth muscle cells and medial/adventitial thinning is a core structural change in AAA.
Platelet-rich intraluminal thrombus
A non-occlusive intraluminal thrombus commonly forms within the dilated aneurysm sac. Human thrombus transcriptomics shows enrichment of platelet-associated transcripts and GPVI, while circulating soluble GPVI associates with aneurysm diagnosis and growth. The thrombus is therefore a biologically active compartment rather than merely an imaging bystander, although its net mechanical and inflammatory effects remain context dependent.
platelet CL:0000233 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves platelet (CL:0000233). CL:0000233 is a cell type from the Cell Ontology.
platelet activation GO:0030168 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased platelet activation (GO:0030168). GO:0030168 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Progressive aortic dilatation Platelet/GPVI activity within the ILT contributes to aneurysm progression in experimental models.
Show evidence (2 references)
PMID:38900973 SUPPORT Human Clinical
"A common feature in patients with abdominal aortic aneurysms (AAAs) is the formation of a nonocclusive intraluminal thrombus (ILT) in regions of aortic dilation."
Human AAA tissue commonly contains a non-occlusive intraluminal thrombus.
PMID:38900973 SUPPORT Human Clinical
"Using RNA sequencing, we identified that the platelet-associated transcripts are significantly enriched in the ILT compared with the adjacent aneurysm wall and healthy control aortas."
RNA sequencing of excised human tissue identifies platelet enrichment within AAA thrombus.
Progressive aortic dilatation
Cumulative loss of wall strength allows progressive dilatation of the infrarenal aorta. Enlargement raises mechanical wall stress and is the main clinically used marker of rupture risk.
vascular smooth muscle cell CL:0000359 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vascular smooth muscle cell, annotated with vascular associated smooth muscle cell (CL:0000359). CL:0000359 is a cell type from the Cell Ontology.
Downstream
Abdominal aortic aneurysm Progressive infrarenal aortic dilatation produces the defining aneurysm phenotype.
Platelet-rich intraluminal thrombus Dilated aneurysm regions commonly develop non-occlusive intraluminal thrombus.
Aortic wall rupture Increasing aneurysm diameter raises the risk of wall rupture.
Pulsatile abdominal mass A sufficiently enlarged aneurysm may be palpable as a pulsatile abdominal mass.
Show evidence (1 reference)
PMID:29945457 SUPPORT Human Clinical
"Abdominal aortic aneurysm (AAA) is characterized by progressive and irreversible dilatation of the aortic wall"
Describes progressive, irreversible aortic-wall dilatation as the defining disease course.
Aortic wall rupture
Rupture occurs when arterial-pressure-driven wall stress exceeds the residual strength of the thinned, matrix-depleted aneurysm wall, producing life-threatening intra-abdominal or retroperitoneal haemorrhage.
Downstream
Aortic rupture Structural failure of the aneurysm wall manifests clinically as aortic rupture.
Abdominal pain Ruptured AAA commonly presents with abdominal pain.
Back pain Ruptured AAA commonly presents with back pain.
Syncope Acute blood loss from ruptured AAA may present with syncope.
Hypotension Ruptured AAA may produce hypotension from internal haemorrhage.
Show evidence (2 references)
PMID:30337540 SUPPORT Human Clinical
"If the mechanical stress of the blood pressure acting on the wall exceeds the wall strength, the AAA ruptures, causing life-threatening intra-abdominal haemorrhage - the mortality for patients with ruptured AAA is 65-85%."
Describes the biomechanical basis of AAA rupture and its high mortality.
PMID:30337540 SUPPORT Human Clinical
"Although AAAs of any size can rupture, the risk of rupture increases with diameter."
Aneurysm diameter is the principal determinant of rupture risk, underpinning diameter-based repair thresholds.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Abdominal Aortic Aneurysm Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Cardiovascular 2
Syncope HP:0001279 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Syncope (HP:0001279). HP:0001279 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35220634 SUPPORT Human Clinical
"Pooled sensitivities of abdominal pain, back pain, and syncope for rAAA were 61.7%, 53.6%, and 27.8%, respectively (low certainty)."
Meta-analysis reports syncope in 27.8% of ruptured-AAA presentations, with low certainty.
Hypotension HP:0002615 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypotension (HP:0002615). HP:0002615 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35220634 SUPPORT Human Clinical
"Pooled sensitivity of hypotension and pulsatile abdominal mass were 30.9% and 47.1%, respectively (low certainty)."
Meta-analysis reports hypotension in 30.9% of ruptured-AAA presentations, with low certainty.
Constitutional 2
Abdominal pain HP:0002027 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abdominal pain (HP:0002027). HP:0002027 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35220634 SUPPORT Human Clinical
"Pooled sensitivities of abdominal pain, back pain, and syncope for rAAA were 61.7%, 53.6%, and 27.8%, respectively (low certainty)."
Meta-analysis identifies abdominal pain as a common, though insensitive, presentation of ruptured AAA.
Back pain HP:0003418 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Back pain (HP:0003418). HP:0003418 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35220634 SUPPORT Human Clinical
"Pooled sensitivities of abdominal pain, back pain, and syncope for rAAA were 61.7%, 53.6%, and 27.8%, respectively (low certainty)."
Meta-analysis identifies back pain as a common, though insensitive, presentation of ruptured AAA.
Other 3
Abdominal aortic aneurysm HP:0005112 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abdominal aortic aneurysm (HP:0005112). HP:0005112 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30337540 SUPPORT Human Clinical
"An abdominal aortic aneurysm (AAA) is a localized dilatation of the infrarenal aorta."
Defines the characteristic lesion of AAA.
Aortic rupture HP:0031649 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aortic rupture (HP:0031649). HP:0031649 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30337540 SUPPORT Human Clinical
"the AAA ruptures, causing life-threatening intra-abdominal haemorrhage"
Rupture with life-threatening haemorrhage is the feared complication of AAA.
Pulsatile abdominal mass HP:6001311 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pulsatile abdominal mass (HP:6001311). HP:6001311 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35220634 SUPPORT Human Clinical
"Pooled sensitivity of hypotension and pulsatile abdominal mass were 30.9% and 47.1%, respectively (low certainty)."
Meta-analysis reports the sign in 47.1% of ruptured-AAA presentations, with low certainty.
🧬

Genetic Associations

1
PCSK9
Gene: PCSK9 hgnc:20001 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PCSK9 (hgnc:20001). hgnc:20001 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (1 reference)
PMID:37845353 SUPPORT Computational
"this was supported by evidence of significant colocalization between PCSK9 protein quantitative trait loci (pQTL) and AAA GWAS at the PCSK9 locus"
Mendelian-randomization and colocalization evidence identifies PCSK9 as an AAA susceptibility locus, not a monogenic cause.
💊

Medical Actions

7
Ultrasound surveillance of small aneurysms
Action: diagnostic ultrasoundNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is diagnostic ultrasound (NCIT:C19337). NCIT:C19337 is a clinical intervention from the NCI Thesaurus. Ontology label: Diagnostic Ultrasound NCIT:C19337
Small, asymptomatic aneurysms below the repair threshold are monitored with serial abdominal ultrasonography, with repair considered as diameter or growth rate increases rupture risk.
Show evidence (2 references)
PMID:38307694 SUPPORT Other
"Management of patients with small abdominal aortic aneurysm (AAA), including surveillance, cardiovascular risk reduction, and indication for repair"
The current ESVS guideline explicitly covers surveillance as part of small-AAA management.
PMID:29268916 SUPPORT Other
"recommended surveillance imaging at 12-month intervals for patients with an AAA of 4.0 to 4.9 cm in diameter."
The SVS practice guideline gives a concrete annual surveillance interval for 4.0-4.9-cm AAA.
Cardiovascular risk-factor modification and smoking cessation
Action: tobacco cessation counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is tobacco cessation counseling (NCIT:C101244). NCIT:C101244 is a clinical intervention from the NCI Thesaurus. Ontology label: Tobacco Cessation Counseling NCIT:C101244
Smoking cessation and control of cardiovascular risk factors are central to conservative management, given that smoking is the strongest modifiable risk factor for developing AAA.
Show evidence (1 reference)
PMID:29945457 SUPPORT Human Clinical
"While smoking prevention and cessation are the most effective strategies in AAA prevention, the effect of smoking on AAA lasts for at least 10 years after smoking cessation."
The prospective AAA cohort report explicitly identifies prevention and cessation as the most effective smoking-focused strategies.
Open surgical repair
Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Elective open surgical repair replaces the aneurysmal aortic segment with a prosthetic graft to prevent rupture; considered once the aneurysm reaches a threshold diameter or rupture risk.
Show evidence (1 reference)
PMID:30337540 SUPPORT Human Clinical
"Elective repair of AAA with open surgery or endovascular aortic repair (EVAR) should be considered to prevent AAA rupture"
Elective open surgical repair is a standard intervention to prevent AAA rupture.
Endovascular aneurysm repair (EVAR)
Action: Endovascular Aneurysm RepairNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Endovascular Aneurysm Repair (NCIT:C157839). NCIT:C157839 is a clinical intervention from the NCI Thesaurus. NCIT:C157839
Endovascular aneurysm repair excludes the aneurysm sac from arterial pressure by deploying a stent graft via the femoral arteries; a less invasive alternative to open repair for anatomically suitable aneurysms.
Show evidence (1 reference)
PMID:30337540 SUPPORT Human Clinical
"Elective repair of AAA with open surgery or endovascular aortic repair (EVAR) should be considered to prevent AAA rupture"
EVAR is a standard, less invasive alternative to open repair for AAA.
Monoclonal-antibody PCSK9 inhibition for AAA prevention (investigational)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: PCSK9 inhibitor NCIT:C190797 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses PCSK9 inhibitor (NCIT:C190797). NCIT:C190797 is a therapeutic agent from the NCI Thesaurus.
PCSK9 inhibition is a genetically prioritized but unproven AAA-prevention strategy. Human genetic analyses associate higher predicted PCSK9 with increased incident AAA risk, and Pcsk9 loss of function reduced aneurysm growth in a mouse model; no AAA-specific clinical efficacy is established.
Mechanism Target:
INHIBITS PCSK9 and atherogenic-lipoprotein susceptibility axis — PCSK9 inhibition is proposed to reduce the PCSK9/non-HDL-lipid susceptibility signal implicated by human genetics.
Show evidence (1 reference)
PMID:37845353 SUPPORT Computational
"human genetic evidence has overwhelmingly suggested that LDL-C reduction is likely to reduce AAA risk."
Human genetic evidence supports inhibition of this susceptibility axis, but not clinical efficacy against AAA.
Show evidence (2 references)
PMID:37845353 SUPPORT Computational
"human genetic evidence has overwhelmingly suggested that LDL-C reduction is likely to reduce AAA risk."
Human genetic evidence supports prevention as a hypothesis, but does not demonstrate clinical benefit from a PCSK9 inhibitor in people with AAA.
PMID:37845353 SUPPORT Model Organism
"our Pcsk9 null mouse model demonstrated reduced AAA growth following elastase infusion"
Pcsk9 loss of function reduced experimental aneurysm growth in mice, an indirect preclinical result that does not establish drug efficacy in human AAA.
Metformin for small-AAA growth suppression (investigational)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: metformin CHEBI:6801 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses metformin (CHEBI:6801). CHEBI:6801 is a therapeutic agent from Chemical Entities of Biological Interest.
Metformin has observational and genetic-epidemiology signals suggesting possible protection, but it is not an established AAA therapy. A small, under-recruited randomized placebo-controlled trial in non-diabetic people found no difference in aneurysm growth; larger trials are needed before any efficacy claim is warranted.
Show evidence (4 references)
PMID:40311839 REFUTE Human Clinical
"No difference in AAA growth between the metformin and placebo groups was observed."
The randomized MetAAA trial did not demonstrate the proposed small-AAA growth-suppression effect.
PMID:40311839 SUPPORT Human Clinical
"Considering the lack of power of the study, larger randomised controlled trials with longer follow up are required to detect smaller treatment effects."
The negative proof-of-concept trial was underpowered, so a smaller effect remains unresolved rather than disproven.
PMID:42487515 SUPPORT Human Clinical
"We found evidence of a protective association between self-reported metformin treatment and reduced AAA risk in the observational analysis, OR 0.49 (95% CI: 0.41-0.59, p = 1.5 × 10-14)."
Observational human data support a protective association for incident AAA but do not establish efficacy against growth of an existing aneurysm.
+ 1 more reference
GABA (investigational)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: gamma-aminobutyric acid CHEBI:16865 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses gamma-aminobutyric acid (CHEBI:16865). CHEBI:16865 is a therapeutic agent from Chemical Entities of Biological Interest.
Gamma-aminobutyric acid (GABA) is an investigational agent shown in a rat AAA model and network-pharmacology analysis to reduce MMP-2/MMP-9-mediated extracellular matrix degradation via inhibition of GABA-A-receptor-dependent PI3K/AKT signaling, delaying aneurysm progression. Preclinical only; no established human role.
Mechanism Target:
INHIBITS Matrix metalloproteinase-mediated aortic wall proteolysis — GABA suppressed MMP-2/MMP-9 activity and extracellular matrix degradation in the aneurysmal aortic wall in a rat model, acting through GABA-A-receptor-dependent PI3K/AKT signaling.
Show evidence (1 reference)
PMID:42410225 SUPPORT Model Organism
"GABA reduced the expression and activity of MMP2 and MMP9, thereby effectively inhibiting ECM degradation and delaying the progression of AAA."
Rat-model evidence directly supports the asserted inhibition of the MMP-mediated proteolysis target.
Show evidence (2 references)
PMID:42410225 SUPPORT Model Organism
"GABA reduced the expression and activity of MMP2 and MMP9, thereby effectively inhibiting ECM degradation and delaying the progression of AAA."
In a rat AAA model, GABA reduced MMP-2/MMP-9 activity and ECM degradation, delaying aneurysm progression.
PMID:42410225 SUPPORT Computational
"KEGG analysis showed that the PI3K/AKT signaling pathway was the key pathway through which GABA exerted its therapeutic effects."
Network-pharmacology (in silico) analysis implicated PI3K/AKT signaling as the key pathway of GABA action in AAA.
🌍

Environmental Factors

1
Tobacco smoking exposure
exposure to tobacco smoking ECTO:6000029 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to tobacco smoking (ECTO:6000029). ECTO:6000029 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Cigarette smoking is the strongest established modifiable risk factor for common AAA and acts across inflammatory, proteolytic, and smooth-muscle-cell injury pathways.
Show evidence (1 reference)
PMID:29945457 SUPPORT Human Clinical
"Smoking is the strongest risk factor for AAA, increasing AAA lifetime risk by 5-fold compared with never smokers."
A disease-specific prospective cohort report identifies smoking as the strongest AAA risk factor and quantifies lifetime risk.
🔬

Biochemical Markers

1
Circulating soluble glycoprotein VI
Context: Soluble GPVI is an investigational platelet-activation biomarker. In two human AAA cohorts it predicted AAA diagnosis and associated with aneurysm growth more strongly than D-dimer; it is not an established stand-alone clinical diagnostic or treatment-selection test.
Pathograph Readouts
Predicts Platelet-rich intraluminal thrombus Positive Prognostic
Higher soluble GPVI reflects platelet activity in AAA-associated thrombus and predicts aneurysm growth.
Show evidence (1 reference)
PMID:38900973 SUPPORT Human Clinical
"Examination of a specific indicator of platelet activity, soluble GPVI (sGPVI), in 2 independent cohorts of patients with AAAs is highly predictive of an AAA diagnosis and associates more strongly with aneurysm growth rate than D-dimer in humans."
Two human cohorts support soluble GPVI as a platelet-linked diagnostic and growth-associated biomarker.
Show evidence (1 reference)
PMID:38900973 SUPPORT Human Clinical
"the levels of sGPVI in humans can predict a diagnosis of AAA and AAA growth rate"
Human cohort evidence supports the investigational biomarker claim without asserting clinical validation.
🔬

Diagnosis

1
Abdominal ultrasonography and CT angiography
AAA is defined as an infrarenal aortic diameter of at least 3 cm. Abdominal ultrasonography is the primary screening and surveillance modality; computed tomography angiography provides detailed anatomic assessment for planning repair. Most intact aneurysms are asymptomatic and detected incidentally or through population screening of older men.
diagnostic procedure NCIT:C18020 NCI Thesaurus (NCIT)
Results: Infrarenal aortic diameter >=3 cm on imaging establishes the diagnosis; larger diameter indicates higher rupture risk.
Show evidence (2 references)
PMID:30337540 SUPPORT Human Clinical
"in settings where screening programmes with ultrasonography are not implemented, most cases are diagnosed incidentally."
Ultrasonography screening and incidental detection are the principal routes to AAA diagnosis.
PMID:27871502 SUPPORT Human Clinical
"evidence showed significant reductions in AAA-related mortality and AAA rupture rate up to 13 to 15 years of follow-up with 42% reduction"
USPSTF systematic evidence review of population trials shows one-time ultrasound screening significantly reduces AAA-related mortality and rupture, the basis for recommending screening in older men who have smoked.
🩻

Imaging Findings

1
Infrarenal aortic dilatation on ultrasonography
Ultrasonographic demonstration of a maximum infrarenal aortic diameter of at least 3 cm establishes the defining imaging lesion and permits serial diameter surveillance.
Ultrasound Diagnostic
Abdominal aortic aneurysm HP:0005112 Human Phenotype Ontology (HP) abdominal aorta UBERON:0001516 Uberon multi-species anatomy ontology (UBERON) Abdominal aortic aneurysm HP:0005112 Human Phenotype Ontology (HP)
Show evidence (1 reference)
PMID:29945457 SUPPORT Human Clinical
"We defined asymptomatic AAA by a maximal infrarenal aortic diameter ≥3 cm."
The ARIC ultrasound protocol uses the standard 3-cm infrarenal diameter criterion.
📊

Prevalence

2
Men aged >=65 years (screening programs)
Point Prevalence 6000.0 per 100,000 (4000.0–8000.0) >1 in 1,000
Screening-program point prevalence in men aged >=65 years (4-8%); AAA prevalence rises with age. From the ARIC study review of AAA epidemiology.
Show evidence (1 reference)
PMID:29945457 SUPPORT Human Clinical
"The prevalence of AAA increases with age and was reported to be 1-2% in women and 4-8% in men aged ≥65 years based on screening programs."
Reports screening-based point prevalence of AAA in men aged >=65 years.
Women aged >=65 years (screening programs)
Point Prevalence 1500.0 per 100,000 (1000.0–2000.0) >1 in 1,000
Screening-program point prevalence in women aged >=65 years (1-2%); AAA prevalence rises with age. From the ARIC study review of AAA epidemiology.
Show evidence (1 reference)
PMID:29945457 SUPPORT Human Clinical
"The prevalence of AAA increases with age and was reported to be 1-2% in women and 4-8% in men aged ≥65 years based on screening programs."
Reports screening-based point prevalence of AAA in women aged >=65 years.
📊

Related Datasets

4
Brown remodeling of white adipose tissue protects against abdominal aortic aneurysm via a novel batokine FSTL1 geo:GSE296628
Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease without effective medical therapies. Emerging evidences have suggested a crosstalk between adipose tissue and vascular cells and brown adipose tissue is beneficial for cardiovascular health. Nevertheless, whether brown remodeling of white adipose tissue would protect against AAA remains unclear. Here we showed that patients with AAA had a decreased browning level of adipose tissue and induction of adipose tissue browning significantly reduced AAA incidence and attenuated AAA development in mice.
human BULK RNA SEQ n=6
PMID:41068431
Identified by GEO DataSets index search for Abdominal Aortic Aneurysm (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
TCF7L2 Promotes Abdominal Aortic Aneurysm through Smooth Muscle Cell-Mediated Extracellular Matrix Remodeling [RNA-seq] geo:GSE329070
Abdominal aortic aneurysm (AAA) lacks effective pharmacological therapies. Here, we investigate transcription factor 7-like 2 (TCF7L2), a genetic locus associated with both thoracic and abdominal aortic aneurysms, to elucidate its role in AAA pathogenesis. Integrating summary-data-based Mendelian randomization (SMR) with single-cell RNA sequencing (scRNA-seq) of human and mouse aortas, we identify TCF7L2 as a gene enriched in vascular smooth muscle cells (VSMCs) and causally linked to AAA development.
human BULK RNA SEQ n=8
PMID:42060473
Identified by GEO DataSets index search for Abdominal Aortic Aneurysm (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
Plasma Proteomics from Subjects with Abdominal Aortic Aneurysm massive:MSV000099209
plasma was collected from subjects with diagnosed abdominal aortic aneurysm
Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Abdominal Aortic Aneurysm"). Retrieved 2026-08-02.
Geisinger eMERGE - Abdominal Aortic Aneurysm Project (AAAP) dbgap:phs000387
A large research cohort of Geisinger Abdominal Aortic Aneurysm (AAA) patients was created by enrolling and consenting patients of the Geisinger Department of Vascular Surgery. Consented patients provide blood, serum and DNA samples for research and authorize use of data in their medical record for research. They also complete a data questionnaire that asks information about family history of AAA and other vascular diseases, as well as information on known or suspected AAA risk factors, including smoking history, body mass index, hypertension, type 2 diabetes, and atherosclerotic disease.
Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Abdominal Aortic Aneurysm"). Retrieved 2026-08-02.
{ }

Source YAML

click to show 
name: Abdominal Aortic Aneurysm
creation_date: "2026-07-11T11:57:18Z"
description: >-
  Abdominal aortic aneurysm (AAA) is a localized dilatation of the infrarenal
  aorta and a common degenerative vascular disease of older adults. It is
  multifactorial, with smoking, male sex, older age, and a positive family
  history as the principal risk factors. The aneurysmal wall is characterized by
  chronic transmural inflammation, matrix metalloproteinase (MMP)-driven
  proteolysis of elastin and fibrillar collagen, medial vascular smooth muscle
  cell depletion, and progressive thinning and weakening of the media and
  adventitia. Aneurysms are typically asymptomatic and enlarge silently; when
  wall stress exceeds wall strength the aneurysm ruptures, causing
  life-threatening haemorrhage with very high mortality. Management centers on
  ultrasound surveillance of small aneurysms, cardiovascular risk-factor
  modification, and elective open or endovascular repair once the aneurysm
  reaches a threshold diameter or rupture risk. This entry models common
  degenerative AAA; infected, inflammatory/IgG4-related, syndromic, and other
  uncommon aneurysm etiologies have distinct mechanisms and are not treated as
  subtypes of common AAA here.
category: Complex
disease_term:
  preferred_term: abdominal aortic aneurysm
  term:
    id: MONDO:0005350
    label: abdominal aortic aneurysm
synonyms:
- AAA
- infrarenal aortic aneurysm
pathophysiology:
- name: PCSK9 and atherogenic-lipoprotein susceptibility axis
  biological_scale: MOLECULAR
  description: >-
    Human genetic analyses implicate non-HDL cholesterol and genetically
    predicted circulating PCSK9 in susceptibility to developing AAA. This is a
    risk axis rather than proof that PCSK9 determines the growth or rupture of
    an established aneurysm.
  genes:
  - preferred_term: PCSK9
    term:
      id: hgnc:20001
      label: PCSK9
  biological_processes:
  - preferred_term: cholesterol metabolic process
    modifier: INCREASED
    term:
      id: GO:0008203
      label: cholesterol metabolic process
  evidence:
  - reference: PMID:37845353
    reference_title: "Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      this was supported by evidence of significant colocalization between
      PCSK9 protein quantitative trait loci (pQTL) and AAA GWAS at the PCSK9
      locus
    explanation: >-
      Mendelian-randomization and colocalization analyses support a PCSK9-linked
      susceptibility mechanism for incident AAA, without establishing an effect
      on growth or rupture of an existing aneurysm.
  downstream:
  - target: Progressive aortic dilatation
    description: >-
      In an elastase mouse model, Pcsk9 loss of function blunted experimental
      AAA growth, linking this susceptibility axis to dilatation in that model;
      this does not establish an effect on established human AAA.
    evidence:
    - reference: PMID:37845353
      reference_title: "Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        our Pcsk9 null mouse model demonstrated reduced AAA growth following
        elastase infusion
      explanation: Mouse loss-of-function evidence supports this edge preclinically, but not as an established human progression mechanism.
- name: Aortic wall inflammatory cell infiltration
  biological_scale: TISSUE
  description: >-
    Chronic transmural inflammation of the aortic wall, with infiltration of
    macrophages and lymphocytes, is an early and sustained feature of AAA. The
    inflammatory infiltrate drives local production of proteolytic enzymes and
    pro-inflammatory cytokines (e.g., IL-6) that promote extracellular matrix
    breakdown and aneurysm progression.
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:37799778
    reference_title: "The contribution of matrix metalloproteinases and their inhibitors to the development, progression, and rupture of abdominal aortic aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pathological observations advocate inflammatory cell infiltration
      alongside adverse extracellular matrix degradation as key contributing
      factors to the formation of human atherosclerotic AAAs.
    explanation: Human pathology observations identify inflammatory cell infiltration as a key contributor to AAA formation.
  - reference: PMID:29945457
    reference_title: "The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      blood concentrations of MMP-9 and IL-6 measured in middle age predicted
      the risk of AAA during 24 years of follow-up.
    explanation: >-
      In the ARIC cohort, circulating IL-6 prospectively predicted future AAA.
      This supports an association with the inflammatory axis but does not by
      itself establish that IL-6 is an upstream causal driver in the aortic wall.
  downstream:
  - target: Matrix metalloproteinase-mediated aortic wall proteolysis
    description: Infiltrating macrophages secrete proteolytic enzymes that degrade the aortic extracellular matrix.
- name: Matrix metalloproteinase-mediated aortic wall proteolysis
  biological_scale: MOLECULAR
  description: >-
    Macrophage- and smooth muscle cell-derived matrix metalloproteinases
    (notably MMP-2 and MMP-9) are the predominant proteinases in the AAA wall.
    A shift in the balance between MMPs and their tissue inhibitors (TIMPs)
    toward net proteolysis drives destruction of the load-bearing matrix. MMP-9
    is elevated in the circulation of patients who later develop AAA.
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  biological_processes:
  - preferred_term: extracellular matrix disassembly
    modifier: INCREASED
    term:
      id: GO:0022617
      label: extracellular matrix disassembly
  evidence:
  - reference: PMID:37799778
    reference_title: "The contribution of matrix metalloproteinases and their inhibitors to the development, progression, and rupture of abdominal aortic aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      macrophage production of proteolytic enzymes is deemed responsible for the
      damaging loss of ECM proteins, especially elastin and fibrillar collagens,
      which characterise AAA progression and rupture.
    explanation: Identifies macrophage-derived proteolytic enzymes as responsible for the matrix loss that characterizes AAA progression and rupture.
  - reference: PMID:29945457
    reference_title: "The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Higher concentrations of MMP-9 and IL-6 were associated with future risk
      of clinically diagnosed AAA
    explanation: >-
      Circulating MMP-9 prospectively associated with future AAA in a human
      cohort. This is consistent with, but does not directly demonstrate,
      MMP-9-mediated proteolysis within the aneurysmal wall.
  downstream:
  - target: Elastin and collagen extracellular matrix degradation
    description: MMP activity degrades the elastin and fibrillar collagen that provide aortic wall strength.
- name: Elastin and collagen extracellular matrix degradation
  biological_scale: TISSUE
  description: >-
    Proteolytic loss of medial elastic lamellae and fibrillar collagen removes
    the principal load-bearing components of the aortic wall. Elastin
    fragmentation reduces recoil and compliance, while collagen degradation
    ultimately compromises tensile strength and predisposes to rupture.
  cell_types:
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  biological_processes:
  - preferred_term: collagen catabolic process
    modifier: INCREASED
    term:
      id: GO:0030574
      label: collagen catabolic process
  evidence:
  - reference: PMID:30337540
    reference_title: "Abdominal aortic aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AAA results from changes in the aortic wall structure, including thinning
      of the media and adventitia due to the loss of vascular smooth muscle
      cells and degradation of the extracellular matrix.
    explanation: The definitive AAA review attributes AAA to extracellular matrix degradation and wall thinning.
  downstream:
  - target: Progressive aortic dilatation
    description: Loss of load-bearing elastin and collagen weakens the wall and permits progressive dilatation.
  - target: Medial smooth muscle cell depletion and wall thinning
    description: Extracellular-matrix degradation is one proposed inducer of medial VSMC apoptosis in AAA.
    evidence:
    - reference: PMID:37799778
      reference_title: "The contribution of matrix metalloproteinases and their inhibitors to the development, progression, and rupture of abdominal aortic aneurysms."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Multiple factors have been proposed to induce VSMC apoptosis including
        oxidised lipoproteins, cytokines, and increased reactive oxygen species
        (41), alongside extracellular matrix degradation (42) and mechanical
        stress (43).
      explanation: A disease-specific narrative review identifies extracellular-matrix degradation as a proposed, rather than established, inducer of VSMC apoptosis.
- name: Medial smooth muscle cell depletion and wall thinning
  biological_scale: CELLULAR
  description: >-
    Apoptosis and loss of medial vascular smooth muscle cells, the cells that
    synthesize and maintain the aortic matrix, thins the media and adventitia
    and impairs the wall's capacity to repair ongoing matrix injury.
  cell_types:
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  biological_processes:
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  evidence:
  - reference: PMID:30337540
    reference_title: "Abdominal aortic aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      thinning of the media and adventitia due to the loss of vascular smooth
      muscle cells
    explanation: Loss of vascular smooth muscle cells and medial/adventitial thinning is a core structural change in AAA.
  downstream:
  - target: Progressive aortic dilatation
    description: A weakened, thinned wall permits progressive aneurysmal dilatation.
- name: Platelet-rich intraluminal thrombus
  biological_scale: TISSUE
  description: >-
    A non-occlusive intraluminal thrombus commonly forms within the dilated
    aneurysm sac. Human thrombus transcriptomics shows enrichment of
    platelet-associated transcripts and GPVI, while circulating soluble GPVI
    associates with aneurysm diagnosis and growth. The thrombus is therefore a
    biologically active compartment rather than merely an imaging bystander,
    although its net mechanical and inflammatory effects remain context dependent.
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: platelet activation
    modifier: INCREASED
    term:
      id: GO:0030168
      label: platelet activation
  evidence:
  - reference: PMID:38900973
    reference_title: "Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic target."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A common feature in patients with abdominal aortic aneurysms (AAAs) is the
      formation of a nonocclusive intraluminal thrombus (ILT) in regions of
      aortic dilation.
    explanation: Human AAA tissue commonly contains a non-occlusive intraluminal thrombus.
  - reference: PMID:38900973
    reference_title: "Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic target."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Using RNA sequencing, we identified that the platelet-associated
      transcripts are significantly enriched in the ILT compared with the
      adjacent aneurysm wall and healthy control aortas.
    explanation: RNA sequencing of excised human tissue identifies platelet enrichment within AAA thrombus.
  downstream:
  - target: Progressive aortic dilatation
    description: Platelet/GPVI activity within the ILT contributes to aneurysm progression in experimental models.
    evidence:
    - reference: PMID:38900973
      reference_title: "Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic target."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        intervention with the anti-GPVI antibody (JAQ1) in mice with established
        aneurysms blunted the progression of AAA in 2 independent mouse models.
      explanation: Anti-GPVI intervention supports a platelet-linked contribution to progression in mice, but does not directly establish the direction or magnitude of ILT feedback in humans.
- name: Progressive aortic dilatation
  biological_scale: TISSUE
  description: >-
    Cumulative loss of wall strength allows progressive dilatation of the
    infrarenal aorta. Enlargement raises mechanical wall stress and is the main
    clinically used marker of rupture risk.
  cell_types:
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  evidence:
  - reference: PMID:29945457
    reference_title: "The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abdominal aortic aneurysm (AAA) is characterized by progressive and
      irreversible dilatation of the aortic wall
    explanation: Describes progressive, irreversible aortic-wall dilatation as the defining disease course.
  downstream:
  - target: Abdominal aortic aneurysm
    description: Progressive infrarenal aortic dilatation produces the defining aneurysm phenotype.
  - target: Platelet-rich intraluminal thrombus
    description: Dilated aneurysm regions commonly develop non-occlusive intraluminal thrombus.
  - target: Aortic wall rupture
    description: Increasing aneurysm diameter raises the risk of wall rupture.
  - target: Pulsatile abdominal mass
    description: A sufficiently enlarged aneurysm may be palpable as a pulsatile abdominal mass.
- name: Aortic wall rupture
  biological_scale: TISSUE
  description: >-
    Rupture occurs when arterial-pressure-driven wall stress exceeds the
    residual strength of the thinned, matrix-depleted aneurysm wall, producing
    life-threatening intra-abdominal or retroperitoneal haemorrhage.
  evidence:
  - reference: PMID:30337540
    reference_title: "Abdominal aortic aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      If the mechanical stress of the blood pressure acting on the wall exceeds
      the wall strength, the AAA ruptures, causing life-threatening
      intra-abdominal haemorrhage - the mortality for patients with ruptured AAA
      is 65-85%.
    explanation: Describes the biomechanical basis of AAA rupture and its high mortality.
  - reference: PMID:30337540
    reference_title: "Abdominal aortic aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although AAAs of any size can rupture, the risk of rupture increases with
      diameter.
    explanation: Aneurysm diameter is the principal determinant of rupture risk, underpinning diameter-based repair thresholds.
  downstream:
  - target: Aortic rupture
    description: Structural failure of the aneurysm wall manifests clinically as aortic rupture.
  - target: Abdominal pain
    description: Ruptured AAA commonly presents with abdominal pain.
  - target: Back pain
    description: Ruptured AAA commonly presents with back pain.
  - target: Syncope
    description: Acute blood loss from ruptured AAA may present with syncope.
  - target: Hypotension
    description: Ruptured AAA may produce hypotension from internal haemorrhage.
phenotypes:
- category: Clinical
  name: Abdominal aortic aneurysm
  description: >-
    Localized dilatation of the infrarenal abdominal aorta, the defining lesion
    of the disease. Intact aneurysms are typically asymptomatic and are often
    detected incidentally or through ultrasound screening.
  phenotype_term:
    preferred_term: Abdominal aortic aneurysm
    term:
      id: HP:0005112
      label: Abdominal aortic aneurysm
  evidence:
  - reference: PMID:30337540
    reference_title: "Abdominal aortic aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An abdominal aortic aneurysm (AAA) is a localized dilatation of the
      infrarenal aorta.
    explanation: Defines the characteristic lesion of AAA.
- category: Clinical
  name: Aortic rupture
  description: >-
    Catastrophic rupture of the aneurysmal aorta producing life-threatening
    retroperitoneal or intra-abdominal haemorrhage; the principal cause of death
    in AAA.
  phenotype_term:
    preferred_term: Aortic rupture
    term:
      id: HP:0031649
      label: Aortic rupture
  evidence:
  - reference: PMID:30337540
    reference_title: "Abdominal aortic aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the AAA ruptures, causing life-threatening intra-abdominal haemorrhage
    explanation: Rupture with life-threatening haemorrhage is the feared complication of AAA.
- category: Clinical
  name: Abdominal pain
  description: >-
    New or worsening abdominal or flank pain may accompany rapid aneurysm
    expansion or rupture; intact aneurysms are usually asymptomatic.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:35220634
    reference_title: "Accuracy of presenting symptoms, physical examination, and imaging for diagnosis of ruptured abdominal aortic aneurysm: Systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pooled sensitivities of abdominal pain, back pain, and syncope for rAAA
      were 61.7%, 53.6%, and 27.8%, respectively (low certainty).
    explanation: Meta-analysis identifies abdominal pain as a common, though insensitive, presentation of ruptured AAA.
- category: Clinical
  name: Back pain
  description: >-
    Back pain can occur with aneurysm expansion or impending rupture.
  phenotype_term:
    preferred_term: Back pain
    term:
      id: HP:0003418
      label: Back pain
  evidence:
  - reference: PMID:35220634
    reference_title: "Accuracy of presenting symptoms, physical examination, and imaging for diagnosis of ruptured abdominal aortic aneurysm: Systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pooled sensitivities of abdominal pain, back pain, and syncope for rAAA
      were 61.7%, 53.6%, and 27.8%, respectively (low certainty).
    explanation: Meta-analysis identifies back pain as a common, though insensitive, presentation of ruptured AAA.
- category: Clinical
  name: Syncope
  description: >-
    Syncope can accompany the acute haemodynamic compromise of ruptured AAA,
    but its absence does not exclude rupture.
  phenotype_term:
    preferred_term: Syncope
    term:
      id: HP:0001279
      label: Syncope
  evidence:
  - reference: PMID:35220634
    reference_title: "Accuracy of presenting symptoms, physical examination, and imaging for diagnosis of ruptured abdominal aortic aneurysm: Systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pooled sensitivities of abdominal pain, back pain, and syncope for rAAA
      were 61.7%, 53.6%, and 27.8%, respectively (low certainty).
    explanation: Meta-analysis reports syncope in 27.8% of ruptured-AAA presentations, with low certainty.
- category: Clinical
  name: Hypotension
  description: >-
    Hypotension may result from retroperitoneal or intraperitoneal blood loss
    after rupture, but it is absent in many presentations.
  phenotype_term:
    preferred_term: Hypotension
    term:
      id: HP:0002615
      label: Hypotension
  evidence:
  - reference: PMID:35220634
    reference_title: "Accuracy of presenting symptoms, physical examination, and imaging for diagnosis of ruptured abdominal aortic aneurysm: Systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pooled sensitivity of hypotension and pulsatile abdominal mass were 30.9%
      and 47.1%, respectively (low certainty).
    explanation: Meta-analysis reports hypotension in 30.9% of ruptured-AAA presentations, with low certainty.
- category: Clinical
  name: Pulsatile abdominal mass
  description: >-
    A palpable pulsatile abdominal mass is a classic but insensitive physical
    sign, more likely with a larger aneurysm.
  phenotype_term:
    preferred_term: Pulsatile abdominal mass
    term:
      id: HP:6001311
      label: Pulsatile abdominal mass
  evidence:
  - reference: PMID:35220634
    reference_title: "Accuracy of presenting symptoms, physical examination, and imaging for diagnosis of ruptured abdominal aortic aneurysm: Systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pooled sensitivity of hypotension and pulsatile abdominal mass were 30.9%
      and 47.1%, respectively (low certainty).
    explanation: Meta-analysis reports the sign in 47.1% of ruptured-AAA presentations, with low certainty.
prevalence:
- population: Men aged >=65 years (screening programs)
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 6000.0
  rate_low: 4000.0
  rate_high: 8000.0
  notes: >-
    Screening-program point prevalence in men aged >=65 years (4-8%); AAA
    prevalence rises with age. From the ARIC study review of AAA epidemiology.
  evidence:
  - reference: PMID:29945457
    reference_title: "The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence of AAA increases with age and was reported to be 1-2% in women and 4-8% in men aged ≥65 years based on screening programs."
    explanation: Reports screening-based point prevalence of AAA in men aged >=65 years.
- population: Women aged >=65 years (screening programs)
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 1500.0
  rate_low: 1000.0
  rate_high: 2000.0
  notes: >-
    Screening-program point prevalence in women aged >=65 years (1-2%); AAA
    prevalence rises with age. From the ARIC study review of AAA epidemiology.
  evidence:
  - reference: PMID:29945457
    reference_title: "The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence of AAA increases with age and was reported to be 1-2% in women and 4-8% in men aged ≥65 years based on screening programs."
    explanation: Reports screening-based point prevalence of AAA in women aged >=65 years.
biochemical:
- name: Circulating soluble glycoprotein VI
  context: >-
    Soluble GPVI is an investigational platelet-activation biomarker. In two
    human AAA cohorts it predicted AAA diagnosis and associated with aneurysm
    growth more strongly than D-dimer; it is not an established stand-alone
    clinical diagnostic or treatment-selection test.
  readouts:
  - target: Platelet-rich intraluminal thrombus
    relationship: PREDICTS
    direction: POSITIVE
    endpoint_context: PROGNOSTIC
    interpretation: Higher soluble GPVI reflects platelet activity in AAA-associated thrombus and predicts aneurysm growth.
    evidence:
    - reference: PMID:38900973
      reference_title: "Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic target."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Examination of a specific indicator of platelet activity, soluble GPVI
        (sGPVI), in 2 independent cohorts of patients with AAAs is highly
        predictive of an AAA diagnosis and associates more strongly with
        aneurysm growth rate than D-dimer in humans.
      explanation: Two human cohorts support soluble GPVI as a platelet-linked diagnostic and growth-associated biomarker.
  evidence:
  - reference: PMID:38900973
    reference_title: "Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic target."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the levels of sGPVI in humans can predict a diagnosis of AAA and AAA
      growth rate
    explanation: Human cohort evidence supports the investigational biomarker claim without asserting clinical validation.
inheritance:
- name: Multifactorial polygenic inheritance
  inheritance_term:
    preferred_term: Polygenic inheritance
    term:
      id: HP:0010982
      label: Polygenic inheritance
  description: >-
    Common degenerative AAA has substantial heritability but no single Mendelian
    inheritance pattern. Risk reflects many common variants together with major
    environmental and demographic factors, particularly smoking, age, and sex.
  evidence:
  - reference: PMID:37845353
    reference_title: "Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abdominal aortic aneurysm (AAA) is a common disease with substantial
      heritability. In this study, we performed a genome-wide association
      meta-analysis from 14 discovery cohorts and uncovered 141 independent
      associations, including 97 previously unreported loci.
    explanation: A large multi-cohort GWAS establishes substantial heritability and a highly polygenic risk architecture.
genetic:
- name: PCSK9
  gene_term:
    preferred_term: PCSK9
    term:
      id: hgnc:20001
      label: PCSK9
  relationship_type: SUSCEPTIBILITY
  notes: >-
    Human genetic evidence links higher genetically predicted circulating PCSK9
    to increased AAA risk. PCSK9 is one prioritized locus within a broad
    polygenic architecture and is not an individually deterministic cause of
    common AAA.
  evidence:
  - reference: PMID:37845353
    reference_title: "Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      this was supported by evidence of significant colocalization between
      PCSK9 protein quantitative trait loci (pQTL) and AAA GWAS at the PCSK9
      locus
    explanation: Mendelian-randomization and colocalization evidence identifies PCSK9 as an AAA susceptibility locus, not a monogenic cause.
environmental:
- name: Tobacco smoking exposure
  presence: Positive
  description: >-
    Cigarette smoking is the strongest established modifiable risk factor for
    common AAA and acts across inflammatory, proteolytic, and smooth-muscle-cell
    injury pathways.
  effect: Increases lifetime AAA risk.
  exposure_term:
    preferred_term: exposure to tobacco smoking
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
  evidence:
  - reference: PMID:29945457
    reference_title: "The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Smoking is the strongest risk factor for AAA, increasing AAA lifetime
      risk by 5-fold compared with never smokers.
    explanation: A disease-specific prospective cohort report identifies smoking as the strongest AAA risk factor and quantifies lifetime risk.
imaging_findings:
- name: Infrarenal aortic dilatation on ultrasonography
  modality: ULTRASOUND
  imaging_finding_term:
    preferred_term: Abdominal aortic aneurysm
    term:
      id: HP:0005112
      label: Abdominal aortic aneurysm
  description: >-
    Ultrasonographic demonstration of a maximum infrarenal aortic diameter of
    at least 3 cm establishes the defining imaging lesion and permits serial
    diameter surveillance.
  located_in:
    preferred_term: abdominal aorta
    term:
      id: UBERON:0001516
      label: abdominal aorta
  phenotype_term:
    preferred_term: Abdominal aortic aneurysm
    term:
      id: HP:0005112
      label: Abdominal aortic aneurysm
  diagnostic: true
  evidence:
  - reference: PMID:29945457
    reference_title: "The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We defined asymptomatic AAA by a maximal infrarenal aortic diameter ≥3 cm."
    explanation: The ARIC ultrasound protocol uses the standard 3-cm infrarenal diameter criterion.
diagnosis:
- name: Abdominal ultrasonography and CT angiography
  description: >-
    AAA is defined as an infrarenal aortic diameter of at least 3 cm. Abdominal
    ultrasonography is the primary screening and surveillance modality; computed
    tomography angiography provides detailed anatomic assessment for planning
    repair. Most intact aneurysms are asymptomatic and detected incidentally or
    through population screening of older men.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  results: Infrarenal aortic diameter >=3 cm on imaging establishes the diagnosis; larger diameter indicates higher rupture risk.
  evidence:
  - reference: PMID:30337540
    reference_title: "Abdominal aortic aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in settings where screening programmes with ultrasonography are not
      implemented, most cases are diagnosed incidentally.
    explanation: Ultrasonography screening and incidental detection are the principal routes to AAA diagnosis.
  - reference: PMID:27871502
    reference_title: "Screening for abdominal aortic aneurysm in asymptomatic adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "evidence showed significant reductions in AAA-related mortality and AAA rupture rate up to 13 to 15 years of follow-up with 42% reduction"
    explanation: >-
      USPSTF systematic evidence review of population trials shows one-time
      ultrasound screening significantly reduces AAA-related mortality and
      rupture, the basis for recommending screening in older men who have smoked.
treatments:
- name: Ultrasound surveillance of small aneurysms
  description: >-
    Small, asymptomatic aneurysms below the repair threshold are monitored with
    serial abdominal ultrasonography, with repair considered as diameter or
    growth rate increases rupture risk.
  treatment_term:
    preferred_term: diagnostic ultrasound
    term:
      id: NCIT:C19337
      label: Diagnostic Ultrasound
  therapeutic_modality: DEVICE
  evidence:
  - reference: PMID:38307694
    reference_title: "Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Management of patients with small abdominal aortic aneurysm (AAA),
      including surveillance, cardiovascular risk reduction, and indication for
      repair
    explanation: The current ESVS guideline explicitly covers surveillance as part of small-AAA management.
  - reference: PMID:29268916
    reference_title: "The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      recommended surveillance imaging at 12-month intervals for patients with
      an AAA of 4.0 to 4.9 cm in diameter.
    explanation: The SVS practice guideline gives a concrete annual surveillance interval for 4.0-4.9-cm AAA.
- name: Cardiovascular risk-factor modification and smoking cessation
  description: >-
    Smoking cessation and control of cardiovascular risk factors are central to
    conservative management, given that smoking is the strongest modifiable risk
    factor for developing AAA.
  treatment_term:
    preferred_term: tobacco cessation counseling
    term:
      id: NCIT:C101244
      label: Tobacco Cessation Counseling
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:29945457
    reference_title: "The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While smoking prevention and cessation are the most effective strategies
      in AAA prevention, the effect of smoking on AAA lasts for at least 10
      years after smoking cessation.
    explanation: The prospective AAA cohort report explicitly identifies prevention and cessation as the most effective smoking-focused strategies.
- name: Open surgical repair
  description: >-
    Elective open surgical repair replaces the aneurysmal aortic segment with a
    prosthetic graft to prevent rupture; considered once the aneurysm reaches a
    threshold diameter or rupture risk.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  therapeutic_modality: SURGERY
  evidence:
  - reference: PMID:30337540
    reference_title: "Abdominal aortic aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Elective repair of AAA with open surgery or endovascular aortic repair
      (EVAR) should be considered to prevent AAA rupture
    explanation: Elective open surgical repair is a standard intervention to prevent AAA rupture.
- name: Endovascular aneurysm repair (EVAR)
  description: >-
    Endovascular aneurysm repair excludes the aneurysm sac from arterial
    pressure by deploying a stent graft via the femoral arteries; a less
    invasive alternative to open repair for anatomically suitable aneurysms.
  treatment_term:
    preferred_term: Endovascular Aneurysm Repair
    term:
      id: NCIT:C157839
      label: Endovascular Aneurysm Repair
  therapeutic_modality: SURGERY
  evidence:
  - reference: PMID:30337540
    reference_title: "Abdominal aortic aneurysms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Elective repair of AAA with open surgery or endovascular aortic repair
      (EVAR) should be considered to prevent AAA rupture
    explanation: EVAR is a standard, less invasive alternative to open repair for AAA.
- name: Monoclonal-antibody PCSK9 inhibition for AAA prevention (investigational)
  description: >-
    PCSK9 inhibition is a genetically prioritized but unproven AAA-prevention
    strategy. Human genetic analyses associate higher predicted PCSK9 with
    increased incident AAA risk, and Pcsk9 loss of function reduced aneurysm
    growth in a mouse model; no AAA-specific clinical efficacy is established.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: PCSK9 inhibitor
      term:
        id: NCIT:C190797
        label: PCSK9 Inhibitor
  target_mechanisms:
  - target: PCSK9 and atherogenic-lipoprotein susceptibility axis
    treatment_effect: INHIBITS
    description: >-
      PCSK9 inhibition is proposed to reduce the PCSK9/non-HDL-lipid
      susceptibility signal implicated by human genetics.
    evidence:
    - reference: PMID:37845353
      reference_title: "Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        human genetic evidence has overwhelmingly suggested that LDL-C
        reduction is likely to reduce AAA risk.
      explanation: >-
        Human genetic evidence supports inhibition of this susceptibility axis,
        but not clinical efficacy against AAA.
  evidence:
  - reference: PMID:37845353
    reference_title: "Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      human genetic evidence has overwhelmingly suggested that LDL-C reduction
      is likely to reduce AAA risk.
    explanation: >-
      Human genetic evidence supports prevention as a hypothesis, but does not
      demonstrate clinical benefit from a PCSK9 inhibitor in people with AAA.
  - reference: PMID:37845353
    reference_title: "Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      our Pcsk9 null mouse model demonstrated reduced AAA growth following
      elastase infusion
    explanation: >-
      Pcsk9 loss of function reduced experimental aneurysm growth in mice, an
      indirect preclinical result that does not establish drug efficacy in human
      AAA.
- name: Metformin for small-AAA growth suppression (investigational)
  description: >-
    Metformin has observational and genetic-epidemiology signals suggesting
    possible protection, but it is not an established AAA therapy. A small,
    under-recruited randomized placebo-controlled trial in non-diabetic people
    found no difference in aneurysm growth; larger trials are needed before any
    efficacy claim is warranted.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: metformin
      term:
        id: CHEBI:6801
        label: metformin
  evidence:
  - reference: PMID:40311839
    reference_title: "Editor's Choice - Metformin to Inhibit Progression of Abdominal Aortic Aneurysm: A Randomised, Placebo Controlled Clinical Trial."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No difference in AAA growth between the metformin and placebo groups was
      observed.
    explanation: The randomized MetAAA trial did not demonstrate the proposed small-AAA growth-suppression effect.
  - reference: PMID:40311839
    reference_title: "Editor's Choice - Metformin to Inhibit Progression of Abdominal Aortic Aneurysm: A Randomised, Placebo Controlled Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Considering the lack of power of the study, larger randomised controlled
      trials with longer follow up are required to detect smaller treatment
      effects.
    explanation: The negative proof-of-concept trial was underpowered, so a smaller effect remains unresolved rather than disproven.
  - reference: PMID:42487515
    reference_title: "Evidence of a Protective Effect of Metformin on Abdominal Aortic Aneurysm Risk: Insights From an Observational Study and Mendelian Randomisation Analysis Using Putative Metformin Targets."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found evidence of a protective association between self-reported
      metformin treatment and reduced AAA risk in the observational analysis, OR
      0.49 (95% CI: 0.41-0.59, p = 1.5 × 10-14).
    explanation: Observational human data support a protective association for incident AAA but do not establish efficacy against growth of an existing aneurysm.
  - reference: PMID:42487515
    reference_title: "Evidence of a Protective Effect of Metformin on Abdominal Aortic Aneurysm Risk: Insights From an Observational Study and Mendelian Randomisation Analysis Using Putative Metformin Targets."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      MR results support this finding, with an estimated decrease in AAA risk of
      43%, OR = 0.57 (95% CI: 0.38-0.88, p = 0.010) per one standard deviation
      (sd) decrease in HbA1c via metformin gene targets, equivalent to the effect
      of a prescribed dose of metformin.
    explanation: Mendelian randomization provides indirect causal support for reduced incident AAA risk, not direct trial evidence of growth suppression.
- name: GABA (investigational)
  description: >-
    Gamma-aminobutyric acid (GABA) is an investigational agent shown in a rat
    AAA model and network-pharmacology analysis to reduce MMP-2/MMP-9-mediated
    extracellular matrix degradation via inhibition of GABA-A-receptor-dependent
    PI3K/AKT signaling, delaying aneurysm progression. Preclinical only; no
    established human role.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: gamma-aminobutyric acid
      term:
        id: CHEBI:16865
        label: gamma-aminobutyric acid
  target_mechanisms:
  - target: Matrix metalloproteinase-mediated aortic wall proteolysis
    treatment_effect: INHIBITS
    description: >-
      GABA suppressed MMP-2/MMP-9 activity and extracellular matrix degradation
      in the aneurysmal aortic wall in a rat model, acting through
      GABA-A-receptor-dependent PI3K/AKT signaling.
    evidence:
    - reference: PMID:42410225
      reference_title: "Exploring the potential mechanism of GABA in the treatment of abdominal aortic aneurysm through network pharmacology and experimental validation."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        GABA reduced the expression and activity of MMP2 and MMP9, thereby
        effectively inhibiting ECM degradation and delaying the progression of
        AAA.
      explanation: Rat-model evidence directly supports the asserted inhibition of the MMP-mediated proteolysis target.
  evidence:
  - reference: PMID:42410225
    reference_title: "Exploring the potential mechanism of GABA in the treatment of abdominal aortic aneurysm through network pharmacology and experimental validation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      GABA reduced the expression and activity of MMP2 and MMP9, thereby
      effectively inhibiting ECM degradation and delaying the progression of
      AAA.
    explanation: In a rat AAA model, GABA reduced MMP-2/MMP-9 activity and ECM degradation, delaying aneurysm progression.
  - reference: PMID:42410225
    reference_title: "Exploring the potential mechanism of GABA in the treatment of abdominal aortic aneurysm through network pharmacology and experimental validation."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      KEGG analysis showed that the PI3K/AKT signaling pathway was the key
      pathway through which GABA exerted its therapeutic effects.
    explanation: Network-pharmacology (in silico) analysis implicated PI3K/AKT signaling as the key pathway of GABA action in AAA.
datasets:
- accession: geo:GSE296628
  title: Brown remodeling of white adipose tissue protects against abdominal aortic aneurysm via a novel batokine FSTL1
  description: Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease without effective medical therapies. Emerging evidences have suggested a crosstalk between adipose tissue and vascular cells and brown adipose tissue is beneficial for cardiovascular health. Nevertheless, whether brown remodeling of white adipose tissue would protect against AAA remains unclear. Here we showed that patients with AAA had a decreased browning level of adipose tissue and induction of adipose tissue browning significantly reduced AAA incidence and attenuated AAA development in mice.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 6
  publication: PMID:41068431
  notes: Identified by GEO DataSets index search for Abdominal Aortic Aneurysm (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE329070
  title: TCF7L2 Promotes Abdominal Aortic Aneurysm through Smooth Muscle Cell-Mediated Extracellular Matrix Remodeling [RNA-seq]
  description: Abdominal aortic aneurysm (AAA) lacks effective pharmacological therapies. Here, we investigate transcription factor 7-like 2 (TCF7L2), a genetic locus associated with both thoracic and abdominal aortic aneurysms, to elucidate its role in AAA pathogenesis. Integrating summary-data-based Mendelian randomization (SMR) with single-cell RNA sequencing (scRNA-seq) of human and mouse aortas, we identify TCF7L2 as a gene enriched in vascular smooth muscle cells (VSMCs) and causally linked to AAA development.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 8
  publication: PMID:42060473
  notes: Identified by GEO DataSets index search for Abdominal Aortic Aneurysm (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: massive:MSV000099209
  title: Plasma Proteomics from Subjects with Abdominal Aortic Aneurysm
  description: plasma was collected from subjects with diagnosed abdominal aortic aneurysm
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Abdominal Aortic Aneurysm"). Retrieved 2026-08-02.
- accession: dbgap:phs000387
  title: Geisinger eMERGE - Abdominal Aortic Aneurysm Project (AAAP)
  description:  A large research cohort of Geisinger Abdominal Aortic Aneurysm (AAA) patients was created by enrolling and consenting patients of the Geisinger Department of Vascular Surgery. Consented patients provide blood, serum and DNA samples for research and authorize use of data in their medical record for research. They also complete a data questionnaire that asks information about family history of AAA and other vascular diseases, as well as information on known or suspected AAA risk factors, including smoking history, body mass index, hypertension, type 2 diabetes, and atherosclerotic disease.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Abdominal Aortic Aneurysm"). Retrieved 2026-08-02.
📚

References & Deep Research

Deep Research

1
Claude Code ▸
Abdominal Aortic Aneurysm (AAA): Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 47 citations 2026-07-26T13:22:08.259970

Abdominal Aortic Aneurysm (AAA): Comprehensive Research Report

1. Disease Information

Overview: Abdominal aortic aneurysm (AAA) is a permanent, localized dilatation of the infrarenal (and occasionally suprarenal/juxtarenal) abdominal aorta to a transverse diameter ≥3.0 cm (or ≥1.5x the expected normal diameter), representing progressive degeneration of all three layers of the aortic wall (intima, media, adventitia) that can culminate in aortic rupture. It is a degenerative pathology of the infrarenal aortic segment characterized by progressive dilation and, in advanced cases, catastrophic rupture with high mortality (PMC10354862).

Key identifiers: - MONDO: MONDO:0005350 (abdominal aortic aneurysm); familial forms MONDO:0024521 and related OMIM entries - OMIM: #100070 (AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 1; AAA1, chromosome 19 locus); #611891 (AAA3); related loci AAA2 and others (OMIM 100070, OMIM 611891) - ICD-10: I71.4 (abdominal aortic aneurysm, without rupture); I71.3 (ruptured abdominal aortic aneurysm) - ICD-11: BD51 (Aneurysm of abdominal aorta) - MeSH: D000783 (Aortic Aneurysm, Abdominal) - Orphanet: Familial abdominal aortic aneurysm is catalogued as a rare disease entity distinct from sporadic/degenerative AAA, which is common and not itself an Orphanet rare-disease designation.

Synonyms/alternative names: AAA; infrarenal aortic aneurysm; aortic ectasia (precursor/milder dilation); "triple A."

Data provenance: Most epidemiological and genetic knowledge derives from aggregated, disease-level resources — national/regional ultrasound screening programs (e.g., UK NAAASP, Scandinavian registries), large biobank GWAS (UK Biobank, Million Veteran Program, FinnGen), vascular surgery registries (VASCUNET, VQI), and meta-analyses — rather than individual EHR chart review, though large single-institution EHR-derived case-control studies (e.g., Danish and Swedish national registries) also contribute substantially.

2. Etiology

Disease Causal Factors

AAA is fundamentally a multifactorial degenerative disease arising from the interaction of hemodynamic wall stress, chronic transmural inflammation, extracellular matrix (ECM) proteolysis, oxidative stress, and vascular smooth muscle cell (VSMC) loss, occurring on a background of genetic susceptibility (PMC10354862). A minority of cases are monogenic, arising from heritable connective-tissue disorders (Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome) or are secondary to infection (mycotic aneurysm) or autoimmune/IgG4-related periaortitis (inflammatory AAA).

Genetic Risk Factors

  • Familial clustering: First-degree relatives of AAA patients have markedly increased risk; family history is itself an established clinical risk factor incorporated into USPSTF screening criteria.
  • Linkage loci: The AAA1 locus on chromosome 19 (OMIM #100070) was among the first mapped familial susceptibility regions (PMC3037298).
  • GWAS-confirmed common variants (candidate-gene and genome-wide, meta-analysis–supported): CDKN2BAS (9p21, rs10757278), DAB2IP, LRP1, SORT1 (rs599839), IL6R (rs2228145), LPA (rs3798220), MMP3, AGTR1, ACE, APOA1 — implicating inflammation, lipid metabolism, and ECM remodeling pathways (PMC10608078; note a 2015 EJVES systematic review found most candidate-gene associations were not robustly replicated — "Abdominal Aortic Aneurysm Genetic Associations: Mostly False?" PMID cited via EJVES).
  • Large-scale multi-ancestry GWAS meta-analysis (Roychowdhury et al., Nat Genet 2023, 55:1831-1842): identified 141 independent associations, including 97 previously unreported loci*, across 39,221 cases and 1,086,107 controls, implicating lipid metabolism, vascular development/remodeling, ECM dysregulation, and inflammation, and highlighting PCSK9 as a druggable target* (Nature Genetics; PMC10632148).
  • Shared genetic architecture with cardiometabolic traits: significant genetic correlation with 21 cardiometabolic traits including coronary artery disease, hypertension, and lipid traits, with cholesterol metabolism and inflammation as the most prominent shared pathways (Nat Commun 2024; PMC11226445).
  • Monogenic/syndromic causes: FBN1 (Marfan syndrome), TGFBR1/TGFBR2 (Loeys-Dietz; also independently associated with AAA in the Dutch population), COL3A1 (vascular Ehlers-Danlos — causes ~2% of familial AAA cases), SMAD3, TGFB2/TGFB3, ACTA2, MYH11, LOX, FBLN4/EFEMP2 — genes essential for aortic wall ECM integrity and TGF-β pathway regulation (PMC10454608; PMC3557640).
  • Familial inheritance pattern: studies of AAA kindreds found ~72% consistent with autosomal recessive-appearing aggregation and ~25% autosomal dominant with incomplete penetrance, though sporadic AAA overall behaves as a complex/polygenic trait.

Environmental Risk Factors

  • Smoking is the single strongest modifiable risk factor: current smokers OR ≈3.28, former smokers OR ≈1.86 versus never-smokers; women who smoke have ~15-fold increased risk versus ~7-fold in men (PMC6313801).
  • Age (risk rises sharply after 65), male sex (4–6:1 prevalence ratio versus women), family history, hypertension, hyperlipidemia/atherosclerosis, COPD, Caucasian ancestry (higher risk than Black, Hispanic, or Asian populations in most cohorts).
  • Protective factor: Diabetes mellitus is paradoxically and consistently associated with reduced AAA risk and slower growth in observational studies — an unusual inverse relationship among cardiovascular risk factors, hypothesized to relate to glycation-related ECM stiffening or metformin exposure.

Protective Factors

  • Genetic: Loss-of-function PCSK9 variants are protective (Mendelian randomization: PCSK9 inhibition proxy OR ≈0.595 for AAA risk); HMGCR inhibition (statins) shows an even stronger protective association (OR ≈0.202) in MR analyses (PMC11367000).
  • Environmental/lifestyle: Regular physical activity, Mediterranean-style diet, and smoking cessation reduce risk; statin and ACE-inhibitor/metformin use associate with slower aneurysm growth in observational cohorts (UK Aneurysm Growth Study, BJS).
  • Estrogen signaling is proposed to be protective in premenopausal women, dampening inflammation, oxidative stress, and proteolysis, contributing to the markedly lower AAA prevalence in women before old age (PMC12927653).

Gene-Environment Interactions

Smoking interacts synergistically with genetic susceptibility (e.g., 9p21/CDKN2BAS and lipid-pathway variants) to amplify inflammatory and proteolytic ECM injury; the shared genetic architecture between AAA and cardiometabolic traits (LDL-cholesterol, hypertension) suggests that lifestyle-modifiable atherogenic burden interacts with an individual's polygenic background to determine whether subclinical aortic wall injury progresses to clinically significant aneurysm.

3. Phenotypes

Most AAA is asymptomatic until large or ruptured, which is why population screening exists.

Phenotype Type Onset/Course Frequency Suggested HP term
Aneurysmal dilation of abdominal aorta (≥3 cm) Physical/imaging finding Adult/elderly onset (typically >60y), chronic-progressive Defining feature HP:0004942 (Abdominal aortic aneurysm)
Asymptomatic (pre-rupture) Clinical course Chronic, often stable for years Majority (>90% of intact AAAs) —
Pulsatile abdominal mass Physical sign Variable, more evident in large AAA Occasional (low sensitivity in obese patients) HP:0100490 (Abdominal mass, if used generically)
Abdominal pain / back pain Symptom Can be episodic (expanding aneurysm) or acute (impending rupture/rupture) Occasional pre-rupture; near-universal with rupture HP:0002027 (Abdominal pain), HP:0003418 (Back pain)
Hypotension/shock (with rupture) Clinical sign Acute Present in ruptured AAA HP:0002615 (Hypotension)
Aortic dissection Complication Acute Uncommon complication HP:0002647 (Aortic dissection)
Distal embolization ("trash foot," blue toe syndrome) Complication Acute/subacute Uncommon (mural thrombus embolization) —
Aortocaval or aortoenteric fistula Complication Acute, rare Rare —
Retroperitoneal hematoma (with rupture) Sign Acute Present with rupture —

Severity/progression: Growth is generally silent and gradual (mean 2.2–3 mm/year, size-dependent — 1.3 mm/year for 3 cm aneurysms up to 3.6 mm/year for larger ones), but can accelerate unpredictably ("rapid expanders," >1 cm/year), which itself is an indication for intervention independent of absolute diameter (PMC10354862).

Quality of life impact: Intact, untreated small AAA under surveillance has minimal day-to-day QoL impact beyond surveillance-related anxiety; QoL is substantially affected post-repair (open repair causes greater short-term morbidity/QoL decrement than EVAR, though long-term QoL converges) and is severely impacted after rupture (high mortality, prolonged ICU stay, multi-organ dysfunction in survivors).

4. Genetic/Molecular Information

Causal genes for monogenic/familial forms: - FBN1 (fibrillin-1, Marfan syndrome) — aneurysms typically root/thoracic but can extend - TGFBR1/TGFBR2 (Loeys-Dietz syndrome) — associated with AAA in Dutch cohort studies; LDS patients have more extensive arterial aneurysms than Marfan - COL3A1 (vascular Ehlers-Danlos syndrome, vEDS) — causes ~2% of familial AAA; high rupture risk at smaller diameters - SMAD3, TGFB2, TGFB3 — TGF-β pathway aortopathies - ACTA2, MYH11, PRKG1, MYLK — smooth-muscle contractile apparatus genes (more classically associated with familial thoracic aortic aneurysm/dissection, but overlapping phenotypic spectrum) - LOX (lysyl oxidase) — elastin/collagen crosslinking; loss of function causes aneurysms in mouse models and rare human cases - FBLN4/EFEMP2 — cutis laxa with arterial tortuosity/aneurysm

Common (polygenic) risk variants (see Etiology section for detail): CDKN2BAS/9p21, DAB2IP, LRP1, SORT1, IL6R, LPA, MMP3, AGTR1, ACE, APOA1, plus the 97 novel loci from the 2023 Nature Genetics meta-GWAS (Roychowdhury et al.) spanning lipid metabolism, ECM, vascular development, and inflammatory gene programs.

Variant classification/type: Monogenic-syndrome variants are typically classified via ACMG/AMP criteria in ClinVar (missense, nonsense, splice-site, and structural variants in FBN1/TGFBR1/2/COL3A1); common AAA-associated GWAS variants are non-coding regulatory SNPs of modest individual effect size, aggregated into polygenic risk scores (PRS) that add predictive value beyond clinical risk factors (Nature Genetics 2023).

Somatic vs. germline: AAA-associated variants are essentially all germline; there is no established somatic-mosaicism mechanism analogous to cancer.

Functional consequences: Loss-of-function ECM/structural variants (FBN1, COL3A1, LOX, FBLN4) → structural fragility of the aortic wall; TGF-β pathway variants → paradoxically increased (dysregulated) TGF-β signaling promoting medial degeneration (shared mechanism with the dismech aortopathy_tgfbeta_dysregulation module); PCSK9 loss-of-function → reduced circulating LDL-cholesterol → reduced atherogenic/inflammatory burden on the aortic wall (protective).

Epigenetics: Single-cell ATAC-seq and epigenomic studies show chromatin remodeling in VSMCs accompanying phenotypic switching in aortic aneurysm/dissection, altering accessibility at contractile-gene loci and driving transitions to synthetic/inflammatory/macrophage-like states ("Epigenetic Induction of Smooth Muscle Cell Phenotypic Alterations in Aortic Aneurysms and Dissections," Circulation 2024).

Chromosomal abnormalities: No characteristic aneuploidy or recurrent structural chromosomal rearrangement is described for sporadic AAA; large deletions/duplications affecting FBN1, COL3A1, or contiguous-gene syndromes (e.g., Williams syndrome region, ELN haploinsufficiency causing supravalvar aortic stenosis/arteriopathy) are relevant to related but distinct arteriopathies rather than typical AAA.

5. Environmental Information

  • Toxins/pollution: Cadmium and other heavy-metal exposures have been epidemiologically associated with AAA risk in some cohort studies, plausibly via oxidative stress; air pollution (PM2.5) has emerging associational data with cardiovascular aneurysmal disease broadly.
  • Occupational exposures: Some studies link occupational noise/vibration and heavy physical labor to elevated blood pressure and cardiovascular strain, an indirect risk contributor; direct occupational-toxin causation for AAA specifically is not well established compared to smoking.
  • Lifestyle factors: Cigarette smoking (dominant factor, dose- and duration-dependent), hypertension, dyslipidemia, sedentary lifestyle, and obesity are the principal modifiable contributors. Alcohol's relationship is less consistent across studies.
  • Infectious agents (mycotic aneurysm): A distinct, less common AAA subtype arises from bacteremic seeding of the aortic wall — historically Salmonella species and Staphylococcus aureus are the classic pathogens for "mycotic" (infected) aortic aneurysms, which behave more aggressively (rapid growth, saccular morphology, higher rupture risk) than degenerative AAA and require antimicrobial therapy plus surgical management (PMC5949581). Syphilitic (tertiary lues) aortitis historically caused aneurysms, predominantly thoracic, now rare.
  • Autoimmune/IgG4-related periaortitis: A distinct inflammatory AAA subtype (sometimes termed "inflammatory abdominal aortic aneurysm," IAAA) is associated with IgG4-related disease in roughly half of cases, part of the chronic periaortitis spectrum (which also includes retroperitoneal fibrosis), characterized by IgG4+ plasma cell infiltration, eosinophils, and lymphoid follicles; it must be distinguished from infectious causes via blood cultures/procalcitonin before immunosuppression is initiated (PMC3595781; PMID 18223321).

6. Mechanism / Pathophysiology

Causal Chain (Degenerative AAA)

Hemodynamic/mechanical wall stress + genetic susceptibility → chronic transmural inflammation (macrophage/T-cell/B-cell infiltration) → protease-antiprotease imbalance (MMP/TIMP dysregulation) → elastin and collagen degradation → VSMC apoptosis and phenotypic switching → medial degeneration and loss of structural integrity → progressive aortic dilation → biomechanical wall-stress increase (Laplace's law: wall tension ∝ pressure × radius) → further dilation → rupture when wall stress exceeds wall strength.

  • Molecular pathways: MMP-2 and MMP-9 (gelatinases) are central proteases that degrade elastin and collagen; an imbalance between MMPs and tissue inhibitors of metalloproteinases (TIMPs) drives unchecked ECM proteolysis (PMC8880357). TGF-β signaling is paradoxically increased (not decreased) in many aortopathies including syndromic AAA-associated conditions, contributing to maladaptive remodeling (KEGG/Reactome: TGF-beta signaling pathway). Renin-angiotensin system signaling (AT1 receptor, angiotensin II) drives VSMC dysfunction and inflammation and is exploited experimentally to induce aneurysms in mice.
  • Cellular processes: VSMC apoptosis, VSMC phenotypic switching (contractile → synthetic/proliferative/inflammatory/macrophage-like/mesenchymal-like states — GO:0035909, aorta smooth muscle differentiation, and GO terms for negative regulation of vascular smooth muscle contraction), macrophage polarization (M1 pro-inflammatory dominant), neutrophil extracellular trap (NET) formation within intraluminal thrombus, T-cell (including cytotoxic CD8+) and B-cell/plasma-cell infiltration, oxidative stress (NADPH oxidase-derived ROS), and mitochondrial dysfunction.
  • Protein dysfunction: Loss of elastin/collagen structural integrity (mechanical); fibrillin-1 microfibril network disruption releasing latent TGF-β (Marfan mechanism); dysfunctional contractile apparatus proteins (ACTA2, MYH11) impairing VSMC mechanosensing.
  • Metabolic changes: Metabolomic profiling of AAA tissue/plasma shows altered lipid (sphingolipid, phospholipid), amino acid, and energy metabolism signatures, some correlating with aneurysm size (PMC8401627); local aortic wall lipid deposition and oxidized LDL contribute to macrophage recruitment (foam-cell-like biology overlapping with the atherogenesis module).
  • Immune system involvement: AAA is now widely conceptualized as a chronic immune-mediated vasculopathy: adaptive immunity (T and B lymphocytes, tertiary lymphoid structures, autoantibodies against aortic wall ECM/elastin) plus innate immunity (macrophages, mast cells, complement activation, neutrophil-derived proteases including neutrophil elastase and MMP-8/9). The intraluminal thrombus (ILT), present in nearly all AAAs, is itself a major site of neutrophil activity, protease release, and hypoxia-driven signaling that perpetuates wall degeneration.
  • Tissue damage mechanisms: Oxidative stress, chronic hypoxia beneath the ILT, proteolytic ECM degradation, mechanical (biomechanical wall stress) fatigue, and VSMC necrosis/apoptosis converge to progressively thin and weaken the media and adventitia.
  • Biochemical abnormalities: Elevated circulating and tissue MMP-9, MMP-2, MMP-12; elevated CRP and IL-6; elevated D-dimer (reflecting chronic intraluminal thrombus turnover — see Diagnostics); reduced elastin content and altered collagen cross-linking (LOX-dependent).
  • Single-cell/spatial transcriptomics: scRNA-seq and spatial transcriptomics of human and murine AAA tissue reveal a VSMC phenotypic landscape including T-cell-like, macrophage-like, and mesenchymal-like modulated VSMC states, two distinct fibroblast subtypes, and a TREM2+ macrophage subtype implicated in aneurysm-specific niches (PMC10184349; PMC12131870; PMC12406718). Lineage tracing demonstrates VSMC-to-fibroblast and VSMC-to-macrophage-like transdifferentiation under aortic stress.
  • Sex-specific mechanistic differences: Estrogen signaling dampens inflammation, oxidative stress, and proteolysis, contributing to lower incidence in premenopausal women; however, once an aneurysm forms, the female aortic wall (differing biomechanical/collagen properties) appears less resistant, explaining higher rupture rates at smaller diameters in women despite lower overall prevalence (PMC12927653; JAHA 2021).

Suggested ontology terms: - GO (biological process): GO:0030198 (extracellular matrix organization), GO:0030574 (collagen catabolic process), GO:0006954 (inflammatory response), GO:0007179 (TGF-beta receptor signaling pathway), GO:0006915 (apoptotic process), GO:0035909 (aorta morphogenesis) - CL (cell types): CL:0000359 (vascular associated smooth muscle cell), CL:0000235 (macrophage), CL:0000084 (T cell), CL:0000542 (lymphocyte), CL:0000576 (monocyte), CL:0000499 (stromal cell/fibroblast-like), CL:0000094 (granulocyte/neutrophil) - CHEBI: CHEBI:29108 (calcium — relevant to CaCl2 model), reactive oxygen species entries - UBERON: UBERON:0002064 (abdominal aorta), UBERON:0001630 (tunica media), UBERON:0002037 (cerebellum — N/A), UBERON:0000317 (extracellular matrix)

7. Anatomical Structures Affected

Organ level: - Primary: Infrarenal abdominal aorta (most common site; UBERON:0002064 abdominal aorta / more specifically the infrarenal segment) — can extend to involve the iliac arteries (aortoiliac aneurysm) or, more rarely, the suprarenal/juxtarenal/pararenal segments and even the visceral-branch–bearing aorta (complex AAA, per the 2024 ESVS classification). - Secondary/complication-related organs: Kidneys (renal ischemia from juxtarenal extension or embolization), lower extremities (distal embolization — "trash foot," acute limb ischemia), gastrointestinal tract (aortoenteric fistula, typically duodenum — UBERON:0002114), colon (ischemic colitis post-repair from IMA sacrifice), spinal cord (rare spinal ischemia post-repair). - Body systems: Cardiovascular system primarily; secondary involvement of renal, gastrointestinal, and neurological (spinal) systems through complications or repair-related ischemia.

Tissue and cell level: - Tunica media (UBERON:0001630) — site of elastin/collagen degradation and VSMC loss - Tunica adventitia — site of adventitial inflammatory infiltrate, vasa vasorum changes - Tunica intima — atherosclerotic change, site of intraluminal thrombus formation - Cell populations: vascular smooth muscle cells (CL:0000359), macrophages (CL:0000235), T lymphocytes (CL:0000084), B lymphocytes/plasma cells, fibroblasts/myofibroblasts, endothelial cells (CL:0000115)

Subcellular level: Mitochondrial dysfunction and oxidative stress in VSMCs; ECM (extracellular region, GO:0005576) as the primary subcellular/extracellular compartment of pathology; lysosomal/autophagic changes described in VSMC senescence within the aneurysmal wall.

Localization: - Most AAAs are infrarenal (below the renal arteries), reflecting relatively lower elastin content, sparser vasa vasorum, and greater hemodynamic wall stress at this segment compared to the thoracic aorta. - Lateralization: Not applicable in the traditional sense (the aorta is a midline structure), though eccentric/asymmetric saccular dilation patterns occur and asymmetric mural thrombus distribution is common.

8. Temporal Development

Onset: - Typical age of onset/detection: 65–85 years; uncommon before age 60 except in syndromic/familial forms (which can present in the 30s–50s). - Onset pattern: Insidious/chronic for degenerative AAA (silent expansion over years to decades); acute presentation occurs only with rupture, dissection, or rapid mycotic/infectious aneurysm growth.

Progression: - Stages: Subclinical dilation (aortic ectasia, 2.5–3.0 cm) → small AAA (3.0–5.4 cm, surveillance range) → large AAA (≥5.5 cm in men, often ≥5.0 cm threshold considered in women, intervention range) → symptomatic/rapidly expanding AAA → contained rupture → free rupture. - Progression rate: Mean growth ≈2.2 mm/year overall; size-dependent (≈1.3 mm/year at 3 cm, up to 3.6 mm/year for larger aneurysms); "rapid expansion" (>1 cm/year or >0.5 cm in 6 months) is a red flag independent of absolute size (PMC10354862). - Course pattern: Generally progressive (steadily enlarging), though growth can be non-linear/erratic in an individual patient; no established spontaneous regression for degenerative AAA (regression, when observed, is typically post-EVAR sac shrinkage). - Duration: Chronic, lifelong once initiated — the disease does not resolve without intervention; the natural endpoint without repair (for aneurysms reaching critical diameter) is rupture.

Patterns: - Remission: Not applicable to degenerative AAA (no spontaneous remission); inflammatory/IgG4-related AAA can respond to immunosuppressive therapy, "healing" the periaortic inflammatory component though not necessarily the aneurysm itself. - Critical periods/intervention windows: The diameter threshold of 5.5 cm in men (5.0–5.5 cm often used in women, reflecting their higher rupture risk at smaller diameters) is the key decision point balancing rupture risk against elective repair risk; rapid-expansion criteria independently trigger earlier intervention.

9. Inheritance and Population

Epidemiology

  • Prevalence: Population-screening studies report 1.6–7.2% among individuals aged 60–65+; a large US screening database found overall prevalence of ~2.82% (2.98% in the 65–75 age band) (JVS 2020; ScienceDirect). Prevalence in women is estimated at roughly one-sixth that of men.
  • Incidence: ~55 per 100,000/year in men aged 65–74, rising to 112 per 100,000/year at 75–84, and 298 per 100,000/year at ≥85 (PMC4687424); incidence is highest in male smokers (274/100,000/year at 65–74).
  • Global burden (GBD 2021): 153,927 deaths from aortic aneurysm globally in 2021 (a 73.9% increase in absolute deaths from 1990, though age-standardized death rate declined 21.4% to 1.86/100,000); 3.1 million DALYs in 2021 (age-standardized rate 36.54/100,000, a 26.5% rate decline despite 62.6% increase in absolute DALYs) — reflecting population aging and growth offsetting per-capita risk reduction from smoking-cessation trends and improved management. Age-standardized death rates continue to rise in low/low-middle SDI regions while falling in high-SDI regions (Frontiers Cardiovasc Med 2025; PMC12137283).

For Genetic Etiology

  • Inheritance pattern: Sporadic/degenerative AAA is multifactorial/polygenic; monogenic syndromic AAA (Marfan, Loeys-Dietz, vEDS) is autosomal dominant. Familial (non-syndromic) AAA clustering shows heterogeneous patterns — studies of AAA kindreds found ~72% with recessive-appearing aggregation and ~25% with apparent autosomal dominant inheritance with incomplete penetrance.
  • Penetrance: Variable and age-dependent even in monogenic forms (e.g., vEDS COL3A1 carriers have high but incomplete lifetime penetrance for a vascular event).
  • Expressivity: Highly variable, even within a single kindred/mutation (e.g., aneurysm location, age of onset, and severity differ among relatives sharing an FBN1 or COL3A1 variant).
  • Genetic anticipation: Not a well-established feature of AAA (unlike repeat-expansion disorders).
  • Founder effects: Not prominently described for degenerative AAA; population-specific allele frequencies at GWAS loci (e.g., differing 9p21 or lipid-locus frequencies) contribute to population risk variation.
  • Consanguinity: Not a major recognized risk factor for typical AAA (contrasts with clearly autosomal recessive Mendelian disorders).
  • Carrier frequency: Not applicable in the traditional recessive-carrier sense; polygenic risk score (PRS) distributions from the 2023 meta-GWAS provide population-level risk stratification instead.

Population Demographics

  • Affected populations: Higher prevalence reported in populations of European ancestry compared with Black, Hispanic, and Asian populations in most US/European cohort studies, though data are less complete for non-European populations globally.
  • Geographic distribution: Historically higher in Northern Europe, UK, Australia, New Zealand, and the US; declining incidence trends reported in several high-income countries attributed to reduced smoking prevalence, while incidence/mortality trends are rising in some lower/middle-SDI regions.
  • Sex ratio: ~4–6:1 (male:female) for intact AAA prevalence; narrower ~2:1 ratio for ruptured AAA incidence, reflecting women's disproportionately higher rupture risk at a given diameter.
  • Age distribution: Overwhelmingly a disease of older adults (>60 years), with risk continuing to rise through the 8th and 9th decades of life.

10. Diagnostics

Clinical Tests

  • Imaging (primary diagnostic modality): Abdominal ultrasound/duplex ultrasonography is the standard screening and surveillance tool (non-invasive, no radiation, validated in RCTs to reduce aneurysm-related mortality). CT angiography (CTA) is the gold standard for pre-operative planning and definitive sizing/morphology assessment; MR angiography (MRA) is an alternative, particularly when iodinated contrast is contraindicated.
  • Biomarkers: Plasma D-dimer shows an incremental, dose-dependent association with AAA presence and has both diagnostic value (particularly in patients with peripheral artery disease, threshold >0.675 mg/L in one study) and prognostic value for predicting future aneurysm expansion (PMC9203886). Elevated CRP, IL-6, and MMP-9 are research-stage biomarkers reflecting the inflammatory/proteolytic burden but are not yet standard-of-care diagnostics.
  • Functional/other tests: Not disease-specific beyond imaging; cardiac and pulmonary functional assessment (echocardiography, PFTs) is relevant peri-operatively given shared atherosclerotic/smoking-related comorbidity burden but does not diagnose AAA itself.
  • Pathology/histopathology (typically post-surgical specimen): Medial elastin fragmentation and loss, VSMC depletion, adventitial and medial lymphoplasmacytic/macrophage infiltration, neovascularization, and (in inflammatory AAA) dense periaortic fibroinflammatory rind with IgG4+ plasma cells in the IgG4-related subtype.

Genetic Testing

  • Not routinely performed for sporadic degenerative AAA.
  • Indicated when: young age of onset (<60 years, especially <50), personal/family history suggestive of a connective tissue disorder (tall stature, joint hypermobility, skin/vascular fragility, ectopia lentis, multiple arterial aneurysms/dissections), or strong multi-generational family history of AAA/TAAD.
  • Approach: Multi-gene aortopathy panels covering FBN1, TGFBR1, TGFBR2, COL3A1, SMAD3, TGFB2, TGFB3, ACTA2, MYH11, MYLM, PRKG1, LOX, FBLN4 etc. are preferred over single-gene testing given phenotypic overlap; whole-exome sequencing is used in atypical/undiagnosed familial aortopathy; chromosomal microarray is not first-line for isolated AAA (more relevant to syndromic multi-anomaly presentations).

Clinical Criteria

  • Diagnosis is essentially definitional by imaging-measured diameter (≥3.0 cm, or focal dilation ≥50% above the expected normal diameter for that aortic segment) rather than a symptom-based clinical criteria set (unlike DSM/consensus-criteria diseases).
  • Differential diagnosis: Aortic dissection, retroperitoneal fibrosis/other retroperitoneal masses, pancreatic pseudocyst, tortuous/ectatic (non-aneurysmal) aorta, para-aortic lymphadenopathy, and — for the inflammatory subtype — IgG4-related disease versus infectious (mycotic) aneurysm (distinguished via blood cultures, procalcitonin, and imaging morphology/growth rate).

Screening

  • USPSTF (2019): Grade B — one-time ultrasound screening for men aged 65–75 who have ever smoked (≥100 cigarettes lifetime). Grade C — selective screening for men 65–75 who have never smoked. Recommends against screening women 65–75 who never smoked with no family history; insufficient evidence for women who smoked or have a family history (USPSTF). A recognized care gap exists for high-risk groups outside current guidelines (e.g., male smokers 45–65).

11. Outcome/Prognosis

Survival and Mortality

  • Rupture mortality: Up to 80% overall case-fatality for ruptured AAA; ~50% of patients die before reaching the hospital; historical reports cite up to 90% mortality, with contemporary surgical series still reporting ~50–75% mortality depending on repair modality and time-to-treatment (StatPearls NBK459176; PMC10354862).
  • US burden: AAA rupture accounts for roughly 15,000 deaths per year in the United States.
  • Sex-specific mortality: In-hospital mortality after rupture is significantly higher in women (41.5%) than men (32.2%); 5-year survival post-rupture repair is 40.7% in men versus 29.1% in women (JAHA 2021).

Morbidity and Function

  • Elective repair (EVAR or open) carries substantially lower perioperative mortality (typically <1–4% for elective EVAR, somewhat higher for open repair) than emergency repair for rupture.
  • Long-term morbidity after EVAR includes endoleak, need for reintervention, and continued surveillance imaging burden; open repair carries greater immediate perioperative morbidity (longer recovery, higher cardiopulmonary complication rate) but historically lower long-term reintervention rates.
  • Complications of untreated/growing AAA: distal embolization, aortoenteric/aortocaval fistula, chronic back/abdominal pain from mass effect.

Disease Course and Recovery

  • Without repair, aneurysms above the critical threshold (≥5.5 cm men) or rapidly expanding continue to enlarge and eventually rupture; smaller aneurysms under surveillance have a low (but non-zero) annual rupture risk (~2%/year for 4.0–5.5 cm).
  • With timely elective repair, prognosis is generally favorable relative to the natural history of large untreated aneurysms.

Prediction

  • Prognostic factors: Aortic diameter (the dominant predictor — 12%/year rupture risk at 5.5 cm, rising to ~35%/year above 6.5 cm), growth rate, female sex, smoking status, hypertension, family history of rupture, wall stress/biomechanical modeling parameters (peak wall stress, wall stress-to-strength ratio), aneurysm sac shape (saccular vs. fusiform), and presence/volume of intraluminal thrombus.
  • Prognostic biomarkers: Elevated D-dimer predicts both diagnosis and future expansion; MMP-9 and inflammatory markers are investigational prognostic candidates.

12. Treatment

Pharmacotherapy

No drug is currently FDA-approved specifically to halt AAA growth or prevent rupture; management of small AAA under surveillance emphasizes cardiovascular risk-factor control. - Statins: Some large screening-population studies (Danish cohorts) show high-dose statin therapy reduces AAA growth rate, need for repair, and adverse outcomes including rupture and death; however, meta-analyses of RCT-level evidence are inconsistent, with some showing no significant growth-rate benefit (PMC2267254; Clinician.com summary). - Doxycycline (MMP-9 inhibition): Reduces aortic wall neutrophil and cytotoxic T-cell content and MMP expression/activation in mechanistic human trials, but no clinical trial has demonstrated efficacy in slowing aneurysm growth or reducing clinical events, and MMP-inhibition strategies overall have not achieved clinical success sufficient to change standard of care (PMID 19364980; Circulation). - Beta-blockers: Observational/cohort signal of possible benefit was not confirmed in three separate randomized controlled trials; beta-blockers do not appear to significantly slow AAA growth. - Metformin: Observational/cohort studies suggest reduced AAA growth and complication risk, but all supporting evidence to date is non-randomized; multiple RCTs (including the Metformin Aneurysm Trial, MAT) are underway/ongoing to establish causal efficacy (PMC8710921). - ACE inhibitors: Associated with slower AAA growth in the UK Aneurysm Growth Study observational cohort (alongside metformin) (BJS 2024). - PCSK9 inhibitors: Mendelian randomization data support PCSK9 as a therapeutic target (genetically proxied inhibition reduces AAA risk), positioning PCSK9 inhibitors as a plausible but not yet clinically proven pharmacotherapy avenue. - Overall assessment: "None of the matrix metalloproteinase inhibition strategies has shown clinical success adequate to replace or modify the current standard of care" for AAA growth suppression; surveillance and timely surgical repair remain the mainstay.

Surgical/Interventional (mainstay of definitive treatment)

  • Endovascular aneurysm repair (EVAR): Preferred first-line modality in most eligible patients per 2024 ESVS guidelines; requires anatomically suitable aneurysm neck/access and durable, well-characterized devices (guidelines now advise against off-label IFU use electively and require ≥10 years durability data for newer devices) (ESVS 2024 guidelines).
  • Open surgical repair: Remains standard for complex anatomy (juxtarenal/pararenal/suprarenal, thoracoabdominal extension — Type IV TAAA) or when EVAR is anatomically unsuitable; centers are now recommended to perform ≥30 AAA repairs annually (≥15 each of open and endovascular) to maintain proficiency.
  • Ruptured AAA (rAAA): EVAR is now Class I recommended as first-line where feasible, based on RCT and large cohort evidence of improved outcomes versus open repair in the emergency setting.
  • Fenestrated/branched EVAR (F/BEVAR): Advanced endovascular options for complex juxtarenal, pararenal, and thoracoabdominal aneurysms, expanded significantly in the 2024 ESVS guideline update (Chapter 8).

Suggested MAXO/NCIT terms: MAXO:0000004 (surgical procedure); NCIT:C15329 (Surgical Procedure); endovascular aneurysm repair and open aortic aneurysm repair as specific procedure terms (NCIT has coded entries for "Endovascular Aneurysm Repair" and "Abdominal Aortic Aneurysm Repair").

Supportive/Behavioral

  • Smoking cessation counseling, blood pressure control, lipid management, and cardiovascular risk-factor optimization are core supportive measures for patients under surveillance (MAXO:0000950 supportive care).
  • Surveillance imaging protocols (ultrasound every 2–3 years for 3.0–3.9 cm, annually for 4.0–5.4 cm) constitute a structured monitoring intervention.

Experimental

  • Multiple ongoing RCTs of metformin (MAT and others), continued investigation of PCSK9 inhibitors and other lipid-modifying agents, and biomechanical/AI-based individualized rupture-risk-score tools (combining precise aortic measurements with clinical factors) are in development (ScienceDirect rupture risk score pilot).

Treatment Strategy

Decision algorithm: size/growth-rate threshold → elective repair candidacy assessment (anatomy, comorbidity, life expectancy, patient preference) → EVAR vs. open repair vs. complex F/BEVAR → lifelong post-EVAR surveillance for endoleak/sac behavior. Personalized/precision approaches remain nascent relative to oncology but increasingly incorporate PRS and biomechanical modeling into rupture-risk stratification.

13. Prevention

Primary Prevention

  • Smoking cessation/avoidance is the single most impactful primary-prevention measure given the dominant, dose-dependent smoking risk.
  • Cardiovascular risk-factor modification (blood pressure control, lipid management, physical activity) reduces overall vascular degenerative burden, plausibly reducing AAA incidence, though AAA-specific primary-prevention RCT evidence (beyond smoking cessation) is limited.
  • No vaccine/immunization strategy is applicable (not an infectious disease in its common degenerative form; antimicrobial prophylaxis is relevant only to mycotic-aneurysm risk populations, e.g., IV drug users, endocarditis patients).

Secondary Prevention (Screening/Early Detection)

  • USPSTF-endorsed one-time ultrasound screening for men 65–75 who have ever smoked (Grade B), demonstrated in population-based RCTs to reduce aneurysm-related mortality.
  • Selective/family-history-triggered screening extends to men who never smoked (Grade C) and is an area of active debate for women with smoking history or family history (currently "insufficient evidence").
  • Structured surveillance imaging intervals for known small AAA constitute secondary prevention of rupture via timely detection of growth crossing intervention thresholds.

Tertiary Prevention

  • Timely elective repair before rupture is the principal tertiary-prevention strategy once an AAA has been diagnosed and reaches threshold size or rapid growth criteria.
  • Post-repair surveillance (particularly post-EVAR imaging for endoleak) prevents late complications from progressing to rupture or reintervention emergencies.

Genetic Counseling

  • Recommended for patients/families with suspected syndromic aortopathy (Marfan, Loeys-Dietz, vascular EDS) or strong multi-generational AAA family history, to guide cascade genetic testing, personalized surveillance intervals, and family planning/risk communication (NSGC/ACMG frameworks apply as for other heritable aortopathies).

Public Health

  • Tobacco-control public health policy (taxation, advertising restriction, cessation program funding) is the most impactful population-level lever given the magnitude of the smoking-AAA association; national screening program implementation (e.g., UK NAAASP, similar Scandinavian and US VA programs) exemplifies organized secondary prevention at scale.

14. Other Species / Natural Disease

  • Taxonomy of naturally affected species: Aortic aneurysms (including AAA-analogous lesions) have been described in horses (Equus caballus, NCBITaxon:9796), dogs (Canis lupus familiaris, NCBITaxon:9615), cats (Felis catus, NCBITaxon:9685), and non-human primates, though naturally occurring degenerative AAA analogous to the common human disease is comparatively rare in companion animals and is more often reported as isolated case reports (dissecting aortic aneurysm in a cat: PMC339563; aortic dissection with posterior paresis in a dog).
  • Copper deficiency models: Copper deficiency is linked to impaired lysyl-oxidase-dependent collagen/elastin cross-linking and aortic aneurysm formation in swine (porcine native AAA model, FASEB 2008) and in copper-deficient Sprague-Dawley rats (intimal/medial arterial disruption); the role of copper deficiency in dogs, cats, or non-human primates is not well established.
  • Veterinary relevance: Aortic aneurysm/dissection in companion animals is clinically significant but uncommon relative to human incidence; when it occurs, it is often associated with underlying connective tissue weakness, infection, neoplastic invasion, or (in horses) parasitic (verminous, Strongylus vulgaris) arteritis rather than the atherosclerotic/smoking-driven degenerative process dominant in humans.
  • Comparative biology: The conserved elastin/collagen-dependent aortic wall integrity mechanism (LOX-dependent cross-linking) is evolutionarily deep, which is why copper-deficiency and Lox-knockout models in rodents and pigs recapitulate key aspects of human AAA pathology despite differing primary triggers.
  • Zoonotic potential: Not applicable — AAA is not a transmissible or zoonotic disease.

15. Model Organisms

AAA lacks a single model that fully recapitulates chronic, spontaneous human AAA; four widely used inducible mouse models dominate the field (JVS-Vascular Science 2021; PMC8577080):

  1. Angiotensin II (AngII) infusion model (typically in Apoe⁻/⁻ or Ldlr⁻/⁻ mice): chronic AngII infusion via osmotic minipump induces suprarenal/thoracoabdominal dissecting aneurysms; captures dissection and aneurysm features but the anatomic location (suprarenal/visceral) differs from typical human infrarenal AAA.
  2. Porcine pancreatic elastase (PPE) perfusion model: intraluminal elastase perfusion of the infrarenal aorta enzymatically degrades elastin, producing reliable infrarenal dilation that best mirrors human AAA especially beyond day 7, though technically demanding.
  3. External/periadventitial elastase application (ePPE): topical elastase applied to the aortic adventitia, avoiding intraluminal manipulation; often combined with oral β-aminopropionitrile (a lysyl oxidase inhibitor) for more advanced/faster aneurysm formation (JoVE 66812).
  4. CaCl2 (calcium chloride) periadventitial application model: produces inflammatory vascular wall thickening and aneurysmal change through a distinct calcification/inflammation-driven mechanism.
  5. Combined elastase + AngII rupture model: by day 28, combined elastase perfusion plus AngII infusion produced dilation progressing to AAA with a 60% rupture rate — one of the few models that reproducibly captures rupture, a key translational gap in single-modality models (PMID 32171859).

Genetic models: Apoe⁻/⁻ and Ldlr⁻/⁻ knockout mice (hyperlipidemic background sensitizing to AngII-induced aneurysm), Fbn1 hypomorphic/knock-in mice (Marfan-like aortopathy, primarily root/ascending phenotype), Lox knockout/hypomorph mice (elastin cross-linking failure, perinatal aortic/arterial rupture), and various MMP/TIMP transgenic and knockout lines used to dissect protease-antiprotease balance.

Other model systems: The porcine native AAA / copper-deficiency model recapitulates a connective-tissue-disorder-like aortic phenotype in a large-animal system more anatomically similar to humans, useful for device/endovascular testing. Zebrafish and Drosophila models of aortic/vessel wall integrity exist for specific gene pathways (e.g., elastin/fibrillin homologs) but are not primary AAA disease models. Human iPSC-derived vascular smooth muscle cells and aortic organoid/explant systems are increasingly used for in vitro mechanistic and single-cell/spatial transcriptomic studies of VSMC phenotypic switching.

Model characteristics/limitations: Mouse models generally fail to spontaneously rupture (a major translational limitation, addressed partially by the combined elastase+AngII model), often affect atypical anatomic locations (suprarenal in AngII model versus infrarenal in humans), and do not fully capture the decades-long chronic degenerative time course of human AAA; large-animal (porcine) and induced-rupture combination models are used to bridge this gap for device testing and rupture-risk mechanistic study.

Applications: Mouse and pig models are used to dissect inflammatory cell contributions (macrophage/T-cell depletion studies), test candidate pharmacotherapies (doxycycline, statins, PCSK9 modulation, metformin) pre-clinically, and validate genetic findings from human GWAS (e.g., functional follow-up of LRP1, SORT1, DAB2IP candidate genes) via knockout/knock-in approaches.

Summary Evidence Table (Key Citable Claims)

Claim Source
141 independent AAA GWAS loci, 97 novel, PCSK9 highlighted as therapeutic target Roychowdhury et al., Nat Genet 2023;55:1831-1842 (link)
Current smoking OR ≈3.28 for AAA; former smoking OR ≈1.86 PMC6313801
Rupture risk 12%/year at 5.5 cm, up to 35%/year above 6.5 cm PMC10354862
Women rupture at smaller diameters, 4x increased frequency at <5.5cm AJP-Heart Circ Physiol; JAHA 2021
MMP-2/MMP-9-TIMP imbalance drives ECM proteolysis PMC8880357
USPSTF: one-time US screening, men 65-75 who ever smoked (Grade B) USPSTF
Doxycycline reduces aortic wall neutrophils/T cells but lacks proven clinical growth-rate benefit PMID 19364980
GBD 2021: 153,927 global AA deaths, 73.9% increase in absolute deaths 1990–2021 Frontiers 2025
PCSK9 loss-of-function protective (OR≈0.595); HMGCR/statin proxy more protective (OR≈0.202) PMC11367000
COL3A1 mutations cause ~2% of familial AAA (vascular EDS) PMC10454608
Combined elastase+AngII mouse model achieves 60% rupture rate PMID 32171859
D-dimer >0.675 mg/L predictive biomarker for AAA in PAD patients PMC9203886

Notes on gaps/uncertainty: A number of candidate-gene AAA associations from earlier literature (pre-2015) were subsequently found to be poorly replicated in systematic review/meta-analysis ("mostly false" per EJVES 2016), underscoring that only the largest, most recent multi-ancestry GWAS meta-analyses (2023–2024) should be treated as high-confidence genetic architecture. Pharmacotherapy evidence for slowing AAA growth (statins, doxycycline, beta-blockers, metformin) remains predominantly observational/mixed, with RCT-level confirmation still pending for most agents (metformin trials ongoing) — no drug currently has proven, guideline-endorsed efficacy for halting AAA progression.